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ABSTRACT
Chronic ethanol exposure results in neuroadaptations that drive the progression
of an alcohol use disorder (AUD). One such driving force is alcohol-induced
neurodegeneration. Neuroinflammation has been proposed as a mechanism underlying
this damage. Although neuroinflammation is a physiological response to damage,
overactivation of its pathways can lead to neurodegeneration. A hallmark indicator of
neuroinflammation is microglial activation, but microglial activation is a heterogeneous
continuum of phenotypes that can promote or inhibit neuroinflammation. Furthermore
acute microglial activation is necessary to restore homeostasis, but prolonged activation
can exacerbate damage. The diversity of microglia makes both the level and timecourse
of activation vital to understanding their role in damage and/or recovery. The current set
of experiments examines the effects of ethanol on microglia within the hippocampus and
entorhinal cortex in a binge model of alcohol-induced neurodegeneration. In the first set
of experiments, the phenotype of microglia activation was assessed using Raivich’s 5stages of activation that separates pro- and anti-inflammatory forms of microglia.
Morphological and functional assessments suggest that ethanol does not elicit classical
microglial activation but instead induces partially activated microglia. In the second set of
experiments, the earliest signs of microglial activation were determined to understand
the initiation of microglial activation. Experiments indicated that activation occurred
subsequent to previous evidence of neuronal damage; however, activation was
accompanied by a loss of microglia and the discovery of dystrophic microglia. The final
set of experiments examined whether alcohol-induced partial activation of microglia
would show a differential response with further alcohol exposure. Experiments showed
that animals previously exposed to ethanol showed a greater response to a second
ethanol insult. Overall, these studies suggest that although alcohol may initially interrupt
the normal microglia response, during abstinence from ethanol a partial activation
phenotype appears that may contribute to recovery. Once activated, however, data
suggest that these microglia are primed and upon subsequent exposure show an
increased response. This heterogeneous microglial response with respect to time does
not necessarily reflect a neuroinflammatory response that would be neurodegenerative
but does imply that chronic ethanol consumption affects the normal neuroimmune
system.
KEYWORDS: microglia activation, alcohol use disorder, neurodegeneration, binge
ethanol exposure, neuroinflammation
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INTRODUCTION
Alcohol Use Disorders
Alcohol Use Disorders: Understanding the Problem
Alcohols are a group of organic compounds that have a hydroxyl functional group
bound to a carbon atom. Due to ethanol’s use in beverages, however, the two carbon
chain alcohol has a notoriety that makes the term ethanol or ethyl alcohol (CH3CH2OH)
synonymous with alcohol in the common vernacular. Consuming alcohol is a common
socially accepted pastime, but habitual drunkenness or alcoholism is a problem that
affects numerous aspects of society including but not limited to public health, the
economy, and public safety (Schomerus et al. 2011). Alcoholism has officially been
defined as a diagnosable medical condition or disease in the United States since 1980
with the production of the third edition of the Diagnostics and Statistics Manual of Mental
Disorders (DSM; Hasin et al. 1996). Prior to the DSM III, alcoholism was only
categorized as a personality disorder (Nathan 1991), but the World Health Organization
removed alcoholism from a personality disorder in 1967 prior to its acceptance in the
DSM (NIAAA 1995). The distinction between a personality disorder and a mental
disease is important because the connotation of disease implies that alcoholism is more
than just a behavioral problem and that treatment with pharmacotherapeutic
interventions is appropriate (White et al. 2002).
The term alcoholism, although universally used to refer to habitual drunkenness, is
actually an outdated term and was originally coined to refer to alcohol poisoning around
1850 by Magnus Huss, a Swedish professor of medicine (Lesch et al. 1990; Marcet
1860). In the DSM-IV, the American Psychological Association (APA) categorizes
problems associated with alcohol misuse into two groups, alcohol abuse and alcohol
dependence. Alcohol abuse and dependence fall under the umbrella term alcohol use
1

disorders (AUDs; American Psychiatric Association 2000). The two categories are
defined by the same characteristics (Table 1.1), but alcohol abuse is defined as
displaying one trait in a 12-month period whereas dependence requires possessing at
least three traits within a 12-month period. These traits are very similar to other
definitions of addiction including the development of tolerance, showing signs of
withdrawal, and preoccupation with the drug of choice (American Psychiatric Association
2000). Other academic bodies such as WHO have similar definitions regarding alcohol
abuse included in the International Classification of Diseases (ICD). The ICD differs in
that it includes compulsivity as a characteristic which is absent in the DSM criteria, but
both the DSM-IV and the ICD traits used to define AUDs have been validated in
independent correlation studies predicting alcohol related problems within the general
population (Grant et al. 2007). The development of these guidelines allows for diagnosis
by clinicians, gives clear definitions for academic research, and most importantly,
provides the general population with a way of understanding the boundaries between
social and problematic drinking.
Table 1.1 Traits of Alcohol Abuse/Dependence
Traits
Characterized by:
 Increased amounts of alcohol required to achieve intoxication
Tolerance
 Diminished effects of the same amount of alcohol over time
 Onset of characteristic withdrawal syndrome for alcohol
including moderate symptoms like anxiety, and headache or
Withdrawal
more severe symptoms like seizure and fever.
 Drinking to relieve withdrawal symptoms
 Persistent desire/unsuccessful efforts to curb drinking
Impaired Control
 Drinking more or for a longer period than intended
 Increased time spent in activities necessary to obtain/use
Preoccupation
alcohol or to recover from the effects of drinking
 Foregoing/reducing important social, occupational, or
Continued Use
recreational activities because of drinking
Despite
 Ignoring persistent/recurrent physical or psychological
Problems
problem that is likely to be caused or exacerbated by drinking
Table 1.1 Traits of an AUD as defined by the DSM-IV (Adapted from (American
Psychiatric Association 2000; Hasin et al. 1996))
2

Despite these long standing institutional classifications, the societal debate whether
alcoholism is a treatable disease or simply an inherent character flaw persists today
(Schomerus et al. 2011). This debate continues in the face of overwhelming evidence
showing altered brain function and structure in alcoholics, which suggest that habitual
drunkenness or alcoholism fundamentally changes the neurobiology of individuals
(Gunzerath et al. 2011). The perception that alcoholism is not a disease is slowly
changing, but increasing the public and scientific communities’ knowledge of the
biological effects of alcoholism assists in advocacy efforts to accept alcoholism as a
disease (Pescosolido et al. 2010). Furthermore, an understanding of alcoholism as a
mental disease promotes treatment seeking by individuals who suffer from alcoholism as
well as inclines counselors and clinicians to encourage the use of pharmacotherapies
(Abraham et al. 2009; Schomerus et al. 2011).
Using the DSM- IV criteria for diagnosis (Table 1.1) , epidemiological studies show
that in the United States AUDs are a common problem with over 8.5% of Americans
fitting the diagnostic criteria within the last twelve months (Grant et al. 2004). This
statistic is even more drastic when considering the lifetime prevalence of AUDs as
almost 50% of men and nearly 25% of women at some point in their life could be
diagnosed with having an AUD (Goldstein et al. 2012). This high prevalence makes
AUDs a societal problem rather than just an individual issue. More than half of the
United States population has a friend or close relative who currently has or previously
suffered from an AUD (Dawson and Grant 1998). Problems associated with alcohol
misuse are not unique to the United States of America as many other nations face
similar issues with alcohol misuse (Bloomfield et al. 2003; Grittner et al. 2012). Even
individuals who choose to completely abstain from alcohol consumption and are
fortunate enough to not have direct social ties to anyone with an AUD are still affected
3

by the rampant use and abuse of alcohol. For example, in 2006, problems associated
with alcohol cost the United States approximately $223.5 billion meaning that it cost
each individual approximately $746 per year regardless of their choice to abstain or drink
(Bouchery et al. 2011). This exorbitant amount includes costs associated with lost
productivity, healthcare issues, criminal justice procedures, property damage, and many
other contributing factors (Bouchery et al. 2011).
The majority of these problems stem from binge drinking (Bouchery et al. 2011).
Binge drinking is defined as five or more drinks for a male or four or more drinks for a
female in a two hour period that results in a blood ethanol concentration (BEC) of at
least 0.08% (NIAAA 2004). A drink consists of one-half US fluid ounces of pure ethanol
which roughly equates to a bottle of beer, one mixed drink, or a glass of wine (Miller et
al. 1991). Clear definitions of what constitutes both a drink and the behavioral outcomes
associated with a particular number of drinks are vital for the public to be able to predict
intoxication behaviors and consider the associated consequences. Fortunately, the
popular media as well as colleges across the nation understand the prevalence of
alcohol abuse and have published this data in multiple formats for the general population
(McCoppin 2012; O'Callaghan 2009); however, people continue to underestimate the
size of a drink, which results in higher alcohol consumption than intended and therefore
higher BECs (White et al. 2003).
The pattern of drinking is crucial as it is a better predictor of both BECs and the
associated problematic outcomes than the type of drink or the lifetime quantity of
drinking (Bobak et al. 2004). For example, although an individual who drinks a nightly
shot of alcohol will consume the same lifetime quantity of alcohol as someone who
abstains during the week but chooses to drink seven beers every Saturday night, the
individual drinking seven beers has a greater likelihood of suffering consequences from
4

the acute effects of intoxication due to higher BECs. These consequences are varied but
include things like poor decision-making (George et al. 2005), risky sexual behavior
(Stappenbeck et al. 2013), and a tendency to be involved in violent crimes as either the
perpetrator or the victim (Boles and Miotto 2003). Table 1.2 shows the effects of different
BECs on intoxication behaviors that underlie the consequences of acute alcohol
intoxication. For example, impaired judgment at BECs above 50mg/dL would be
associated with poor decision-making. The legal limit in most states 80mg/dL was set
based on the relationship between BEC and consequces such as the impairments in
motor function seen at above a 0.08 that can lead to increased vehicular accidents
(Villaveces et al. 2003; Whetten-Goldstein et al. 2000). Although other factors can
influence BECs such as sex, genetic differences in alcohol metabolism, and body mass
index (Koob and Le Moal 2006), the number of drinks is the most common predictor
used to understand intoxication and has been shown to be associated with the greater
risks and alcohol-related problems (Fillmore and Jude 2011; Koob and Le Moal 2006).
Table 1.2 Outcomes Associated with Different BECs
BEC
Number of
BEC (%)
Outcomes
(mg/dL)
Drinks
Increased sociability; talkativeness;
10-50
0.01-0.05
1-2
disinhibition; anxiolytic; euphoria
Significant disinhibition; impaired judgment
50-150
0.05-0.15
2-5
cognitive and motor function, sedation
Major motor impairments; slurred speech;
150-200
0.15-0.20
5-6
delayed reaction time
Hypnotic effects; stuporous but conscious
200-300
0.20- 0.30
6-9
behavior
300+
0.30+
9+
Anesthesia; coma; death
Table 1.2 Outcomes associated with various BECs and the number of drinks to achieve
the range for a 140 pound male. The second column shows the more commonly used
blood alcohol percent by law enforcement and the media (Adapted from (Koob and Le
Moal 2006) )
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Although acute intoxication may lead to some of the societal problems from alcohol
misuse, continual episodes of excessive drinking and its corresponding high BECs
results in more permanent changes to organ systems. These biological effects caused
by alcohol are considered causative in at least 30 diseases and may make individuals
more susceptible to countless others (Rehm 2011; Room et al. 2005). Moreover, these
biological changes promote the development of dependence by creating traits like
tolerance through alterations of alcohol metabolism or the perception of the drug
rewarding effect of alcohol in the central nervous system (CNS; Djordjevic et al. 1998;
Gilpin and Koob 2008).
Alcohol Use Disorders: Alcohol as a Reward
The euphoria associated with a drug or the “high” is one of the central mechanisms
by which drugs, including ethanol, are rewarding (Koob and Le Moal 2001). This high
occurs due to changes in neurotransmission particularly in the “feel good”
neurotransmitters, dopamine and serotonin (Gilpin and Koob 2008). The rewarding
affects of alcohol can occur at low concentrations as shown in Table 1.2 (Boileau et al.
2003). However, repetitive use of drugs of abuse can cause neuroplastic changes that
alter the normal hedonic systems of neurotransmission (Der-Avakian and Markou 2012).
In prolonged periods without the drug in the system, the neuroplastic changes lead to a
feeling of dysphoria or a “low” leading to a sense of craving for the drug (Der-Avakian
and Markou 2012; Markou et al. 1998).
Alcohol can also be rewarding due to its anxiolytic effects (Wallner et al. 2003;
Wallner et al. 2006). Many people consume ethanol for its soothing effects, but similar to
chronic ethanol’s effects on hedonic systems, repeated exposure alters the
neurotransmitter systems associated with anxiety causing neuroplastic changes that
produce hyperexcitability (Engin et al. 2012). Addiction, in this instance AUDs, is
6

therefore driven by both the rewarding (euphoric and anxiolytic) effects of intoxication
and the agitating (dysphoric and anxiogenic) effects caused by ethanol (Koob and Le
Moal 2001; Koob and Volkow 2010; Lingford-Hughes et al. 2010). This introduction will
cover how neurodegeneration from chronic alcohol exposure can affect cognition and
indirectly affect the rewarding characteristics of alcohol as these studies are intended to
find novel targets to reduced alcohol brain damage. However, the current AUD
therapies have direct actions on ethanol reward by altering neurotransmitter systems
and will be discussed first.
Alcohol Use Disorders: Ethanol Pharmacology
The rewarding effects of alcohol are due to ethanol’s neuropharmacological actions,
but chronic use alters these systems such that the absence of the drug leads to
dysphoria (Clapp et al. 2008). While some drugs of abuse are known to bind to a specific
receptor disrupting hedonic pathways of neurotransmission, alcohol pharmacology is
more complex due to its physical and chemical properties (Vengeliene et al. 2008). For
example, one theory is that ethanol, as a small, amphiphilic molecule, can displace
water preferentially due to its attraction to both hydrophobic and hydrophilic targets
(Klemm 1998). The displacement of water can then affect the confirmation state of
receptors making alcohol an allosteric effector of various neurotransmitter systems
(Klemm 1990). The multitude of ethanol effects on various neurobiological substrates
makes a full review of alcohol pharmacology within this dissertation impossible;
therefore, this brief synopsis will focus on the major effects of ethanol’s rewarding effects
by discussing the cholinergic and opioid systems as it relates to euphoria as well as the
balance of GABAergic and glutamatergic systems as it relates to the anxiolytic effects of
alcohol. Furthermore, these systems were chosen because the majority of the current
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pharmacotherapy interventions for AUDs or alcohol withdrawal target these systems.
Each system and the respective drug that targets the system will be discussed briefly.
Cholinergic System & Varenicline
Acute ethanol can change the binding of endogenous acetylcholine, particularly to
the nicotinic acetylcholine receptors (nAChR; Cardoso et al. 1999; Zuo et al. 2004).
nAChR's are ionotropic receptors consisting of a single, pentameric transmembrane
channel. The composition of the pentamer alters the alcohol effects on nAChR (Cardoso
et al. 1999; Narahashi et al. 1999; Zuo et al. 2002). At low concentrations, alcohol acts
as co-agonist enhancing cholinergic binding in receptors with α2 and α4 subunits
(Marszalec et al. 1999). This increased ligand binding and ethanol’s ability to stabilize
the open channel state enhances the influx of Na+ depolarizing cells, increases the
probability of an action potential propagation, and results in the increased release of
neurotransmitters (Forman and Zhou 1999). Acute ethanol’s effects on the cholinergic
system, particularly on the α4β2 subtype, can therefore increase dopaminergic signaling
and create a sense of euphoria (Blomqvist et al. 2002; Borghese et al. 2003;
McGranahan et al. 2011). The transient, increased dopamine concentration created by
ethanol’s action on nAChR is only one way that alcohol is rewarding (Soderpalm et al.
2009).
Because of ethanol’s effects on the cholinergic system, varenicline, a partial agonist
of the α4β2 nAChR subtype, has been proposed as a drug of interest for AUDs.
Varenicline can reduce alcohol consumption and seeking but is not yet approved by the
US Food and Drug Administration (FDA) for the treatment of AUDs (Mitchell et al. 2012;
Steensland et al. 2007). Its actions are thought to be associated with reduced euphoria
caused by acute alcohol intoxication through the reduction of the cholinergic effects on
dopamine release (Ericson et al. 2009; Hendrickson et al. 2010).
8

Opioid System & Naltrexone
The euphoria associated with ethanol use is not only caused by alcohol’s action
on the cholinergic system but can also be linked to its effects on the opioid system
(Vengeliene et al. 2008). The endogenous opioid system consists of a group of G
protein-coupled receptors (GPCR's) and their associated ligands like dynorphins,
enkephalins, and endorphins (Bodnar 2012). Acute ethanol stimulates the release of
opioid peptides, especially β-endorphin (Gianoulakis 2001; Warren and Hewitt 2010).
This increase in endogenous opioids has a euphoric effect due to the opiate systems
relationship to the dopaminergic system (Gianoulakis 2001; Spanagel et al. 1990).
However, the effects of chronic ethanol exposure are not as clear, but some reports
indicate alcohol increases µ-opioid receptors as a compensatory mechanism of chronic
alcohol’s effect to reduce the binding of endogenous opioids to receptors (Djouma and
Lawrence 2002).
The effects of ethanol on the opioid system mean that manipulating the system
affects the rewarding capacity of alcohol. Naltrexone is a µ-opioid receptor antagonist
that is indicated for AUD treatment by the FDA. The efficacy of naltrexone is due to its
ability to antagonize the µ-opioid receptor and therefore reduce the effects of alcoholinduced increased β-endorphin (Littleton and Zieglgansberger 2003; Ray et al. 2010).
The reduction in endogenous opiates reduces the ethanol-induced dopaminergic
increase and euphoric effects of alcohol (Kato 2008; Valenta et al. 2013). Naltrexone
has shown some efficacy in AUD treatments by increasing drug abstinence and/or
reducing the number of drinks (Lee et al. 2012; Pettinati et al. 2011).
Glutamatergic System & Acamprosate
As stated earlier, ethanol can also be rewarding outside of the euphoric high due
to its sedative or anxiolytic effects. Some of the anxiolytic effects are associated with
ethanol’s pharmacological actions within the glutamate system, the major excitatory
9

system (Tsai and Coyle 1998). Although alcohol can affect various types of glutamate
receptors, studies on the effects of alcohol on the glutamatergic system generally focus
on the N-methyl-D-aspartate receptor (NMDAR). The focus on the NMDAR stems from
research showing that low doses of alcohol inhibit NMDA-activated Ca2+ calcium influx
(Lovinger et al. 1989). The reduction in excitation from ethanol’s effects on the NMDAR
system underlies the anxiolytic effects of acute alcohol exposure (Tsai and Coyle 1998).
Chronic exposure, however, causes upregulation of the NMDARs on the cell surface of
neurons (Sheela Rani and Ticku 2006). This upregulation of NMDARs can cause a state
of hyperexcitation when ethanol is acutely withdrawn and is associated with severe
withdrawal symptoms like seizures and convulsions (Hoffman 1995; Tsai and Coyle
1998). Moreover, the neuroplastic changes induced by chronic ethanol exposure in
NMDAR activity and expression make the system more sensitive to glutamate
(Vengeliene et al. 2008). Alcohol’s effects on the glutamatergic system will be revisited
later in this dissertation as it also considered a source of neuronal damage.
Acamprosate is an FDA approved therapy that targets the effects of ethanol on
the glutamatergic system. It is the most readily prescribed treatment for alcoholism
although its use is still relatively low (Mark et al. 2009). As a weak partial agonist of
NMDAR, acamprosate reduces the dysphoria in alcohol withdrawal by attenuating
hyper- glutamatergic signaling (Mann et al. 2008; Umhau et al. 2010). A reduction in the
negative affects associated with alcohol deprivation afforded by acamprosate is thought
to reduce relapse and make it useful in the treatment of AUDs (Heilig and Egli 2006).

GABAergic System & Benzodiazepines
Ethanol not only depresses the major excitatory neurotransmitter system, but
also enhances the transmission of the major inhibitory neurotransmitter, γ-aminobutyric
acid (GABA; Vengeliene et al. 2008). Ethanol’s allosteric effects on the GABAA receptor
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in conjunction with its glutamatergic effects play a large role in the anxiolytic state
associated alcohol (Koob 2004; Tsai and Coyle 1998). Like the other neurotransmitter
systems, alcohol has the ability to affect various subtypes of GABA receptors, but it has
particular actions on the GABAA receptor (Kumar et al. 2009; Lobo and Harris 2008).
GABAA receptors are ligand gated ion channels but, being inhibitory, are responsible for
the efflux of the anion Cl- when activated (Spitzer 2010). Low doses of ethanol, increase
the binding of GABA to its receptor through an allosteric mechanism, but
electrophysiology studies have shown that high, but physiologically relevant
concentrations of ethanol can also have direct effects on the GABA receptor in the
absence of GABA (Aguayo et al. 2002). Regardless of whether alcohol allosterically
alters the receptor or directly acts as a ligand, the anion influx hyperpolarizes neurons so
that there is a reduction in synaptic transmission. The depressed synaptic transmission
state is associated with the rewarding, sedative hypnotic properties of alcohol (Koob
2004). However, chronic ethanol exposure causes an internalization of GABA receptors
and reduces the ability of agonists to bind (Golovko et al. 2002). The resulting reduced
GABAergic tone is thought to lead to a state of hyperexcitability and anxiogenic effects
of alcohol withdrawal (Golovko et al. 2002; Koob 2004).
To reduce this hyperexcitation state, benzodiazepines, GABAA agonists, have
been used effectively for years to reduce acute alcohol withdrawal symptoms (Doble
1999; Mayo-Smith 1997; Ntais et al. 2005). However, benzodiazepines are not approved
as an FDA treatment for AUDs as they ameliorate acute withdrawal effects but do not
necessarily affect the rewarding effects of alcohol (Ntais et al. 2005). Although alcohol
causes neuroplastic changes in GABAergic system, benzodiazepines, unlike the
aforementioned medications, are not effective in reducing alcohol intake because they
do not change the actual perception of alcohol but rather treat a symptom.
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Disulfiram
Not all drugs used for AUD therapy have been based on changes in
neurobiology. Disulfiram is also an FDA approved drug for AUDs whose action is mainly
based on inhibiting the metabolism of alcohol within the liver. Disulfiram inhibition of the
enzyme acetaldehyde dehydrogenase causes a buildup of an ethanol metabolite,
acetaldehyde (Jorgensen et al. 2011). Increases in acetaldehyde cause nausea,
headaches, and various other negative reactions so that drinking ethanol produces an
immediate aversive effect (Barth and Malcolm 2010). Although disulfiram has been
shown to have some neurobiological effects on reward and craving (Barth and Malcolm
2010; Grant and Dawson 1998), its aversive nature makes patient compliance and
therefore clinical utility within AUDs problematic (Jorgensen et al. 2011). Like
benzodiazepines, disulfiram’s main effects are not on the addictive effects of alcohol;
however, varenicline, naltrexone, and acamprosate use within AUD therapy are great
examples of how determining chronic ethanol’s neuroplastic changes associated with
the progression of addiction led to treatment options (Chou et al. 1998). Unfortunately,
the efficacy of these drugs in the general population is still low and suggests that
alternatives therapeutic targets need to be discovered.
Alcohol Use Disorders: Neurodegeneration & Cognitive Deficits
Not only does excessive alcohol consumption alter functional aspects of the brain
like neurotransmission that can drive AUD development, it can also result in more global
structural changes through cellular damage (Crews and Nixon 2009; Harper 2009). The
use of therapies that target the neuroadaptations in neurotransmission caused by
chronic ethanol exposure suggests that, as another neuroplastic change, alcoholinduced neurodegeneration may also be a potential target for AUD therapies. Currently,
no FDA approved drug specifically targets alcohol-induced brain damage (Wang et al.
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2010). Although alcohol-induced neurodegeneration can be associated with thiamine
deficiency, alcoholic brain damage, as discussed herein, will refer only to damage
independent of nutritional deficiency and not Wernicke-Korsakoff’s syndrome (Thomson
et al. 2012). Furthermore, the focus will be on brain damage that occurs from AUDs as
opposed to the neuronal loss that may endure from prenatal exposure as seen in fetal
alcohol spectrum disorders (FASD; Klintsova et al. 2007; Lewis et al. 2012; West and
Goodlett 1990).
Scientific debates regarding alcohol-induced brain damage have a long history but were
initially based on deficits in cognition seen in alcoholics due to methodological limitations
(Freund 1973; Freund and Walker 1971). The first quantitative study looking at alcohol
related brain damage in humans showed a reduction in weights of alcoholic individuals’
brains compared to social drinkers (Harper and Blumbergs 1982). However, with the
advent of new techniques such as magnetic resonance imaging (MRI), studies have
been able to show more specific brain regions within alcoholics that have reduced
volume compared with moderate, social drinkers (Pfefferbaum et al. 1992; Pfefferbaum
et al. 1995; Sullivan et al. 1995; Zahr et al. 2011). This damage includes a loss of both
cortical grey and white matter resulting in thinner gyri and increased sulci and lateral
ventricles in alcoholics (Mann et al. 2001; Pfefferbaum et al. 1992; Pfefferbaum et al.
1995). Post-mortem examinations of the brains of alcoholics concur with MRI findings
showing reductions in volume and/or neuronal cell number of various regions (Agartz et
al. 1999; Phillips et al. 1987). These regions include the cerebellum (Baker 1999; Phillips
et al. 1987; Sullivan et al. 2010), hippocampus (Agartz et al. 1999; Beresford et al. 2006;
Sullivan et al. 1995), corpus callosum (Pfefferbaum 1996; Pfefferbaum and Sullivan
2002), and cortical regions especially the frontal lobe (Pfefferbaum et al. 1992;
Pfefferbaum et al. 1997). Others, however, have not seen differences in the
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hippocampus of alcoholics (Harper 1998), but the majority of studies indicate volume
loss or damage . It is important to denote that neurodegeneration does not necessarily
occur in all individuals that drink, but instead, alcohol-induced brain damage correlates
with chronic, excessive ethanol consumption levels and particularly binge drinking (Hunt
1993; Lisdahl et al. 2013).
Although neurodegeneration is not directly related to the rewarding effects of alcohol
pharmacologically, neuronal damage can indirectly affect feelings of reward as well as
alter other behavioral attributes associated with AUD development and addiction (Crews
and Boettiger 2009; Kelley and Mittleman 1999; Koob and Le Moal 1997).
Neurodegeneration within a specific brain region as well as damage to the integrity of its
circuits can be correlated to decline in behaviors associated with that region (AlfonsoLoeches and Guerri 2011; Zahr et al. 2011). For example, damage seen in the frontal
cortex of the mesocorticolimbic pathway has been associated with poor executive
function (Bechara 2005; Dawson and Grant 1998; Medina et al. 2008; Pfefferbaum et al.
1997). Damage to this region caused by ethanol is also thought to be the cause of
increased impulsivity observed in alcoholics in tasks like delayed discounting procedures
(Crews and Boettiger 2009; Petry 2001). Decreased executive function and increased
impulsivity leads to the poor decision making concerning alcohol and may be one of the
reasons that alcoholics have problems with drug preoccupation (Crews 2008; Gilpin and
Koob 2008; Parsons 1993).
Neurodegeneration-induced behavioral deficits can promote a “spiral of addiction”
(Crews 1999; Koob and Le Moal 1997). The spiral of addiction involves the promotion of
alcohol intake by various factors that influence one another in a cyclical pattern. For
example, an individual who starts off drinking moderate volumes of ethanol may
progressively consume more ethanol due to drug tolerance. Tolerance to ethanol can
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develop from various biological changes including increased drug metabolism
(Djordjevic et al. 1998), altered alcohol neuropharmacology (Vengeliene et al. 2008),
and behavioral adaptations that allow for normal functioning during intoxication (VogelSprott 1997). Regardless of the type of tolerance, the result is increased ethanol
consumption which can cause neurodegeneration in the frontal lobes (Pfefferbaum et al.
1992; Sullivan et al. 1995). Neurodegeneration then compromises the ability of the
alcoholic individual to make good decisions regarding ethanol consumption (Crews et al.
2005). This theory highlights how the structural neuroplastic changes in just one region
of the brain caused by excessive alcohol consumption can promote alcohol abuse.
Herein, the focus will be on neurodegeneration within the hippocampus and the
entorhinal cortex. The hippocampus is important for learning and memory and has been
postulated to have a role in drug addiction by its control of drug-dependent memories
and influence on the prefrontal cortex (Hyman et al. 2006; Nixon et al. 2011). The
hippocampus is connected with frontal cortical regions by glutamatergic efferent
neurons, so hippocampal damage can also affect behaviors associated with the frontal
lobe (Godsil et al. 2013). Because the entorhinal cortex and the hippocampus are highly
interconnected (Burwell and Amaral 1998), damage to in the entorhinal cortex also
affects hippocampal integrity and contributes to cognitive deficits (Bott et al. 2013;
Harich et al. 2008). The hippocampus and entorhinal cortex were chosen as
compromised hippocampal integrity in alcoholics has been proposed to underlie
behavioral deficits observed in executive function as well as working memory (Beresford
et al. 2006; Chanraud et al. 2010). Furthermore, the model used in this dissertation has
repeatedly produced damage in both the entorhinal cortex and the hippocampus across
many labs (Collins et al. 1996; Kelso et al. 2011; Obernier et al. 2002a).
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Alcohol Use Disorders: Models of Alcohol-Induced Neurodegeneration
Many models of alcohol exposure exist due to the complex nature of the
contributing factors of AUD progression. People drink for a variety of reasons; therefore,
no single model is enough to fully understand alcoholism. Herein, only the subset of in
vivo rodent models that produce alcohol-induced neurodegeneration are discussed, but
reviews are available that discuss models that examine other aspects of alcoholism such
as the rewarding effects and the behavioral effects of intoxication (Crabbe et al. 2011;
Ripley and Stephens 2011). Models that specifically elicit alcohol-induced
neurodegeneration are necessary in order to understand the mechanisms that lead to
brain damage in alcoholics and can therefore participate in the progression of AUDs by
contributing to the spiral of addiction previously described. Unfortunately, most animals
do not voluntarily consume ethanol at the high concentrations associated with
neurodegeneration. Some labs circumvent this problem by using in vitro studies that
expose neuronal and/or glial tissue cultures to different concentrations and durations of
ethanol that cause neuronal damage or evidence of stress (Fernandez-Lizarbe et al.
2009; Prendergast et al. 2004). However, animal models have to use forced ethanol
exposure to study the phenomenon of alcohol-induced neuronal loss (Crews et al. 2004;
Crews and Nixon 2009). These categories fall under four basic categories of ethanol
exposure: injections, vapor exposure, chronic feeding, or intragastric gavage.
Importantly, these models mimic damage in brain regions and the cognitive deficits seen
in alcoholic patients. Intragastric gavage will be the method used throughout the work
presented herein but other methods will be discussed briefly subsequently.
Intraperitoneal (ip) injections of ethanol can produce evidence of
neurodegeneration. In studies using this model, animals received 3g/kg of ethanol via ip
injections for two consecutive days with two day gaps without injections over a two week
or month long period (Lundqvist et al. 1995; Pascual et al. 2007). This intermittent
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pattern over at least a two week period causes damage in the cerebellum, hippocampus,
and neocortex (Lundqvist et al. 1995; Pascual et al. 2007). Neurodegeneration in this
particular model appears to be dependent upon repeated cycling of high BECs and
withdrawal phases (Lundqvist et al. 1995; Lundqvist et al. 1994). This neuronal damage
also causes cognitive problems including persistent alterations in the hippocampal
associated task of object recognition (Barker and Warburton 2011; Pascual et al. 2007).
The ip route of ethanol administration is problematic as it does not necessarily mimic
alcohol kinetics associated with the typical oral route of alcohol administration in the
human population which makes translating results from these studies difficult
(Adalsteinsson et al. 2006; Iwaniec and Turner 2013).
Similar to the ip injections, there are problems with the face validity associated of
alcohol vapor inhalation models of AUDs (Mattucci-Schiavone and Ferko 1986; Ripley
and Stephens 2011). Although there have been recent reports in the popular media of a
trend of alcohol inhalation (Sifferlin 2013), drinking oral ethanol is still by far the most
common route of intoxication. Vapor studies vary on the dose, duration, and pattern of
ethanol exposure (Gilpin et al. 2008), but the derivation with chronic intermittent vapor
exposure has shown evidence of neurodegeneration in the hippocampus (Ehlers et al.
2013). The vapor model of alcohol-induced neurodegeneration not only alters the
cognitive abilities directly associated with brain damage but also has behavioral
correlates associated with other traits of alcoholism including increased selfadministration (Gilpin et al. 2009; O'Dell et al. 2004). Despite having some behavioral
attributes of an AUD, bypassing the normal metabolic pathways of ethanol makes the
vapor inhalation models problematic as inhaling alcohol produces different behavioral
outcomes than oral administration (Mattucci-Schiavone and Ferko 1986).
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The last two model types that will be discussed have better face validity in that
they both at least use an oral route of ethanol administration which is most similar to the
human condition (Bell et al. 2012). Chronic feeding models rely on self-administration
over months whereas the intragastric gavage uses forced intubation over a relatively
short timeline. In the chronic feeding models, ethanol is the only source of fluid in
drinking water but not food (Rintala et al. 1997). The chronic feeding models produce
damage in the cerebellum, hippocampus, as well as peripheral neuropathy (Cohen et al.
2007; Mellion et al. 2013; Walker et al. 1980). Intragastric gavage models shows similar
damage but can be done over the course of a few days in rats or about a week in mice
making them less time intensive than the chronic feeding model (Collins et al. 1996;
Crews 2008; Hayes et al. 2013; Kelso et al. 2011; Qin and Crews 2012a; Qin and Crews
2012b).
These experiments use a modified version of the Majchrowicz model which
exposes rats to alcohol over a four-day period (Majchrowicz 1975). The Majchrowicz
model has been chosen to as it mimics the multiple days of binge drinking seen in
human alcoholics (Faingold 2008; Tomsovic 1974). It also produces BECs comparable
to a subset of alcoholics with higher tolerance that are functional at BECs well above
300mg/dL due to years of alcohol (Cartlidge and Redmond 1990; Urso et al. 1981).
Chronic feeding models have lower BECs that may not reflect the alcohol concentrations
seen in tolerant alcoholics (Cohen et al. 2007; Mellion et al. 2013). Furthermore, this
model produces other traits characteristic of AUDs including tolerance and withdrawal
(Table 1.1; Crews and Nixon 2009; Crews 2008). Because tolerance varies among
individuals, the Majchrowicz model mimics the human condition and tailors the dose
based on behavior unlike other models of alcohol-induced neurodegeneration
(Majchrowicz 1975; Penland et al. 2001). Specifics about the procedures of the
18

Majchrowicz model will be described in the methods section of chapter two, but
importantly, it is used here because it produces characteristics traits of AUDs, is a model
of binge drinking, and causes neurodegeneration (Crews and Nixon 2009; Crews 2008).
Because all of these aspects of ethanol consumption contribute to AUD progression, the
Majchrowicz model represents a valid paradigm for understanding alcohol abuse.

Alcohol Use Disorders: Mechanisms of Alcohol-Induced Neurodegeneration
Animal models of alcohol-induced neurodegeneration in conjunction with studies of
human alcoholics have increased the understanding of alcoholic brain damage and led
to four general proposed mechanisms of neuronal loss: glutamate excitotoxicity, reduced
neurogenesis, oxidative stress, and neuroinflammation. Glutamate excitotoxicity
involves excess levels of glutamate or increased sensitivity of glutamate receptors that
leads to excessive Ca2+ influx, neuronal dysfunction and neurodegeneration
(Ankarcrona et al. 1995; Lau and Tymianski 2010). During intoxication, ethanol acts as
an NMDA antagonist, but as previously stated, chronic ethanol exposure causes an
upregulation and supersensitivity of NMDA receptors (Chandler et al. 1993a; Chandler et
al. 1993b; Hoffman 1995). In vivo studies also suggest that the upregulation and
supersensitivity of NMDA receptor results in excess glutamate in the system during
withdrawal (Dahchour and De Witte 2003; Grant et al. 1990). Moreover, NMDA receptor
antagonists like acamprosate and MK-801 reduce ethanol withdrawal-induced
glutamatergic spikes and neurotoxicity (Dahchour et al. 1998; De Witte et al. 2005;
Mayer et al. 2002; Prendergast et al. 2004). Together, these studies suggest that
glutamate excitotoxicity is a factor in alcohol-induced neurodegeneration, perhaps
specifically due to ethanol withdrawal.
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A second proposed mechanism of alcohol-induced neurodegeneration is decreased
adult neurogenesis (Nixon and Crews 2002). Unlike the glutamate excitotoxicity role of
degeneration which focuses on cell death from alcohol withdrawal, alcohol-induced
decreases in neurogenesis are seen during intoxication in the absence of withdrawal
(Crews and Nixon 2009; Nixon 2006). In the mammalian postnatal brain, neurogenesis
constitutively occurs in the hippocampal subgranular zone of the dentate gyrus (DG) as
well as in the subventricular zone of the lateral ventricles (Altman and Das 1965;
Doetsch et al. 1999; Eriksson et al. 1998). Neurogenesis is a process that can be
divided into four components: proliferation, differentiation, migration/integration, and
survival (Gage 2000). Reductions in neural progenitor cell proliferation and the longterm survival of newborn cells have specifically been observed in the Majchrowicz model
used within these experiments, and studies using vapor exposure concur (Morris et al.
2010a; Nixon and Crews 2002; Richardson et al. 2009). Reduced cell proliferation and
neuronal cell survival have both been seen in other neurodegenerative diseases with
cognitive deficits (Marxreiter et al. 2013; Ransome et al. 2012) and provide another
mechanism by which alcohol abuse could lead to neuronal cell loss (Nixon 2006; Nixon
and Morris 2008).
Oxidative stress, specifically an increase in reactive oxygen species (ROS) and the
depletion of antioxidant defenses, is associated with neuronal cell death in a variety of
neurodegenerative diseases including Alzheimer’s and Parkinson’s disease (Reynolds et
al. 2007). ROS production can cause mitochondrial dysfunction and lead to cellular loss
(O'Rourke et al. 2005). Postmortem studies of alcoholic brains indicate there are
increases in enzymes associated with ROS production (Qin and Crews 2012b). Models
of alcoholic brain damage including the Majchrowicz model concur with findings in
alcoholics showing increases in nicotinamide adenine dinucleotide phosphate (NADPH)
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oxidase and cyclooxygenase-2 (COX-2) which resulted in tissue damage by producing
free radicals (Knapp and Crews 1999; Qin and Crews 2012a; Qin and Crews 2012b;
Reynolds et al. 2007). Alternatively, alcohol-induced oxidative stress can be due to ROS
produced directly by the metabolism of ethanol at high BECs. Cytochrome P450 2E1
(CYP2E1) preferentially metabolizes alcohol within certain brain regions causing an
increase in ROS production (Haorah et al. 2005; Haorah et al. 2008; Ronis et al. 1993).
Furthermore, chronic ethanol exposure induces CYP2E1 protein levels, mRNA
expression, and activity (Heit et al. 2013; Zhong et al. 2012). Increased ROS production
further promotes an environment of oxidative stress by causing mitochondrial
dysfunction (Nixon et al. 2009; Reddy et al. 2013).
Although glutamate excitotoxicity disrupted neurogenesis, and oxidative stress were
discussed as separate causative factors of degeneration, in reality they can contribute to
each other’s pathological pathways and likely act in conjunction to lead to
neurodegeneration pathways. The final proposed mechanism of ethanol-induced brain
damage, neuroinflammation, will be discussed in more detail as it is a focus of this series
of experiments. Moreover, the influence of the neuroimmune system, specifically
microglia, within each of the other proposed mechanisms of neurodegeneration will also
be discussed.
Neuroinflammation
Inflammation is the biological response to noxious stimuli such as invading
pathogens, foreign chemicals, or cellular damage. In the periphery, the inflammatory
response is characterized by five basic components caused by intracellular immune
signaling events (feelings of pain, flushing, swelling, heat, and a subsequent functional
deficit; Graeber et al. 2011). Inflammation is the result of an immune response which
includes both innate and adaptive immunity. It was originally hypothesized that the
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blood brain barrier (BBB) made the CNS an immune impervious system because of the
lack of rejection of xenografts by rat brain (Murphy and Sturm 1923). However, the
discovery of the innate immune cell, microglia, and their phagocytic capacity within the
CNS completely changed this view (Neuwelt and Clark 1978; Penfield 1925). As the
innate immune cell, microglial activation alone is often referred to as neuroinflammation,
but the heterogeneous nature of microglia makes equating neuroinflammation solely to
microglial activation problematic (Carson et al. 2007; Carson et al. 2006). A more
encompassing, appropriate definition of neuroinflammation incorporates a complex
system consisting of three distinct processes: disruption of the blood-brain barrier,
infiltration of T and B lymphocytes, and activation of microglia/macrophages (Carson et
al. 2006; Hickey 2001).
The initial discovery of the BBB came in 1885 when it was observed that the injection
of dye into the circulatory system did not result in staining of brain tissue (de Vries et al.
1997). Since this initial observation, the actual composition of the BBB has been
elucidated. The BBB is a complex system of endothelial cells, astrocytic end feet,
perivascular macrophages, and the basal lamina that acts as a barrier separating
circulating blood from the brain (Pachter et al. 2003). Disruption of this protecting
cellular network is a key component of neuroinflammation as the BBB acts to separate
the CNS from various immunomodulators (Hickey 2001). The BBB can be disrupted by
mechanical injury such as in traumatic brain injury (Readnower et al. 2010) or by
chemical agents that alter the integrity of cells or transporters (Haorah et al. 2007a;
Haorah et al. 2005).
When the BBB is disrupted, small lymphocytes from the peripheral system can then
enter the parenchyma (Fritz et al. 2000). This infiltration initiates the adaptive immune
response involving two basic types of lymphocytes: T cells and B cells. T helper cells,
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cluster of differentiation (CD) 4+, recognize major histocompatibility complex (MHC)
class II found on antigen-presenting, activated microglia (Gutcher and Becher 2007;
Wraith and Nicholson 2012; Xu and Ling 1994). Upon presentation of antigens by
MHC-II molecules, T helper cells become activated and begin to proliferate and secrete
autocrines attracting cytotoxic T cells (CD 8+; Wraith and Nicholson 2012). Cytotoxic T
cells bind to MHC-I on the damaged cell and secrete various cytotoxins including
perforins and granulysin that leads to cell death (Whitmire 2011). B-cells also mobilize
in response to pathogens and bind to T helper cells because of the MHC-II present on B
cells (Montecino-Rodriguez and Dorshkind 2006). These cells form an interface known
as the immunological synapse that connects the adaptive immune B and T cells with
innate immune antigen-presenting cells like activated microglia/macrophages (Davis et
al. 1999). The cells within this synapse work in concert with one another to elicit a true
neuroinflammatory event and lead to cell death through downstream cell signaling
pathways (Chakraborty et al. 2010). Although various cells participate in both the innate
and adaptive immune system, the focus of this work is on microglia; therefore microglia
and their role in neuroinflammation and within the neuroimmune system will be
discussed in greater detail.
Microglia
Microglia are a type of glia or non-neuronal cell within the CNS. The term
microglia literally means “small glue”: “small” as in the relative size of microglia
compared with other glial cells and “glue” because glial cells were originally thought to
hold neurons together (Dermietzel and Spray 1998). However, microglia play a more
dynamic role in neuronal homeostasis than simply gluing neurons together (Allen and
Barres 2009). Microglia differ from other glial cells such as oligodendrocytes and
astrocytes in their origin, morphology and function. Microglia are derived from
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hematopoietic cells from precursors that eventually have a macrophage fate rather than
neuronal precursor cells (Saijo and Glass 2012; Vilhardt 2005). The origin of microglia
makes them uniquely suited to act as an indicator of neuroinflammatory activity. The
term indicator was chosen because, as stated earlier, microglial activation alone is not
synonymous with neuroinflammation (Hickey 2001). Moreover, both the morphology
and function of microglia are diverse, which will be discussed subsequently.
Microglia: Pro versus Anti-Inflammatory State
Microglia become activated in response to various stimuli including neuronal
damage, noxious agents, astrocytic secretion, and even more minute neuronal
environmental cues like alterations in ion concentrations; however the microglial
activation varies or is heterogeneous based on the intensity or type of damage as well
as the duration of the insult (Harting et al. 2008; Lai and Todd 2008). Microglia display
heterogeneity in their morphology, cytokine secretions, and cell surface proteins (Carson
et al. 2007). Distinctions in these attributes are used to categorize microglia in an
attempt to understand their function within the CNS under pathological conditions.
Although the names used within each classification system are different, the basic
premise of all of the classification systems is that microglia are either proinflammatory or
anti-inflammatory. For example, Heuschling and colleagues use the terms M1 and M2
to differentiate between pro and anti-inflammatory microglia (Mantovani et al. 2002;
Michelucci et al. 2009); whereas, others have simply used the terms classical or
partial/alternative activation to describe the heterogeneity of microglial activation (De
Simone et al. 2004; McClain et al. 2011). In chapter two, these terms will be broken
down even further to reflect the continuum of phenotypes within the proinflammatory and
anti-inflammatory states (Raivich et al. 1999a; Raivich et al. 1999b).
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In normal, non-pathologic conditions, microglia are in a quiescent state often
referred to as “resting.” The term “resting” microglia is a misnomer as quiescent
microglia are not actually without function. They are constantly surveying their
environment, responding to minute changes within the neuronal milieu (Nimmerjahn et
al. 2005). Quiescent microglia have ramified branches from their cell bodies that are
used to survey their environment (Fishman and Savitt 1989; Raivich et al. 1999a), but
activation by noxious stimuli (i.e. cellular damage, ROS, etc.) alters the morphology of
microglia (Brown and Neher 2010; Kettenmann et al. 2011). Resting ramified microglia
transform to a “bushy” morphology (Figure 1.1). This bushy shape is characterized by
the branches/projections thickening and retracting as well as an enlargement of the cell
body (Abraham and Lazar 2000; Morioka et al. 1991; Nimmerjahn et al. 2005). Bushy
shaped microglia are often called the partially activated or M2 microglia (Karperien et al.
2013; Raivich et al. 1999a). Upon further or more intense perturbation, the cell becomes
rounded in shape as it loses thickened processes and pseudopodia used for motility.
Amoeboid microglia are the “classically” defined stage of activated microglia (Figure 1.1;
Raivich et al. 1999a).
Figure 1.1 Morphological Diversity of Microglia

Figure 1.1 Depictions of morphological heterogeneity within microglia activation
continuum (adapted from Nimmerjahn et al. 2005).
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Because microglial activation is truly a continuum of states, a change in
microglial shape alone is not enough to determine whether a cell is pro-versus antiinflammatory. However, changes in the proteins expressed within the cell accompany
the morphological metamorphosis. These alterations in protein expression reflect a
change in the function of the microglia. For example, complement receptor 3 (CR3) is
an integrin present in all microglia, but its expression is upregulated as a result of
chemokines secreted by damaged cells (Akiyama and McGeer 1990; Newton and Hogg
1998). Increased CR3 expression helps microglial cells adhere and anchor to damaged
cells as a step in the phagocytic process (Akiyama and McGeer 1990; Hynes 1992;
Newton and Hogg 1998). Moreover, phagocytosis of damaged cells also alters microglia
protein expression. When microglia internalize or engulf damaged cells, internal
proteases (e.g. cathespin S and L) degrade the damaged cell’s proteins into MHC-II and
the complex is expressed on the cell surface of microglia (Gresser et al. 2001; Nakanishi
2003). Antigen-presenting microglia are a key component of neuroinflammation and the
immune synapse as discussed previously. Expression of MHC-II changes the
classification of the microglia to a more proinflammatory state (Nakanishi 2003; Xu and
Ling 1994) .
Changes in microglia morphology and proteins expressed results in
corresponding alterations in secreted cytokines and growth factors that further reflect the
function of the cell within the neuronal environment as pro- or anti-inflammatory. For
instance, partially activated microglia secrete the anti-inflammatory cytokine interleukin10 (IL-10) which can suppress other neuroinflammatory factors (Braat et al. 2006;
Michelucci et al. 2009). IL-10 suppresses the production of proinflammatory factors by
preventing the activation of nuclear factor kappa-light chain enhancer of activated B cells
(NF-κB; Correa et al. 2010; Heyen et al. 2000). NF-κB is a transcription factor that is
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both activated by and induces the neuroimmune response in a canonical pathway
(Kaltschmidt et al. 2005; Vallabhapurapu and Karin 2009). On the other end of the
spectrum, when microglia become fully or classically activated, they secrete
proinflammatory cytokines like tumor necrosis factor-alpha (TNF-α). Unlike IL-10, TNF-α
increases the production of NF-κB as well as members of the caspase family which
elicits cascades that promote an inflammatory environment (Gaur and Aggarwal 2003).
Altogether, morphological differences coupled with changes in proteins expressed and
cytokines secreted can be used to assess the function and role of microglia under
pathological conditions. Markers used within this dissertation to assess the state of
microglia are presented in figure 1.2.
Figure 1.2 Pro- and Anti-inflammatory Microglial Markers

Figure 1.2 Selected markers used within to characterize microglia. Those markers that
do not directly indicate pro- or anti-inflammation are placed in the middle.

Microglia: Acute versus Chronic Activation
Although proinflammatory microglia are generally thought to be associated with
neuroinflammatory-induced neurodegeneration, the timing of activation and the duration
of activation also plays a major role in whether microglia contribute to
neurodegeneration. Proinflammatory microglial activation does not always result in
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excess damage but can also be associated with recovery. An early, immediate
activation of microglia is necessary for recovery. For example, acute microglial activation
has been described as participating in “housekeeping” (Nimmerjahn et al. 2005) and
“nursing” (Streit 2002b) in the CNS. Activated microglia migrate to damaged areas, and
depending on the level of activation, they begin to secrete neurotrophic factors (nurse) or
remove debris (housekeep; Petersen and Dailey 2004; Takayama and Ueda 2005). This
migration is triggered by chemokines released by damaged neurons and by macrophage
colony stimulating factor (MCSF) released by other microglia (Davalos et al. 2005; Gao
and Ji 2010; Raivich et al. 1991). MCSF can also promote the proliferation of microglia
in response to damage (Carrier et al. 2004; Kloss et al. 1997). This response increases
the microglia in the area that are supporting damaged cells and removing neurons
beyond repair (Carson et al. 2007).
However, the chronic activation of microglia is associated with neuronal loss and
has been proposed as a mechanism within various neurodegenerative diseases (Amor
et al. 2010). For example, in traumatic brain injury, microglial activation persists well
after the initial focal brain injury and causes secondary damage outside of the original
mechanical injury (Lenzlinger et al. 2001; Ramlackhansingh et al. 2011). While
differences in the type of activation can affect the contributions of microglia to
neurodegeneration, the timing and duration of microglial activation is just as important to
understand whether these pro- and anti-inflammatory roles are indicative of
neurodegeneration or are participating in recovery from damage.
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Microglia: Glutamate Excitotoxicity, Oxidative Stress, & Neurogenesis
Glutamate Excitotoxicity
Not only are microglia indicators of potential neuroinflammation, but microglia
also have roles in the other proposed mechanisms of ethanol brain damage: glutamate
excitotoxicity, oxidative stress, and reduced neurogenesis. The excessive glutamate
levels that mediate glutamate excitotoxicity occur because of both increased release as
well as decreased uptake. Microglia have the capacity to affect both processes that
control glutamate excitotoxicity. For example, TNF-α secreted by activated microglia
can initiate the release of glutamate from microglia cells (Takeuchi et al. 2006; Yin et al.
2012). Microglial release of glutamate could contribute to glutamate excitotoxic alcoholinduced neurodegeneration. However, activated microglial cells also upregulate their
expression of the glutamate transporter 1 (GLT-1; Persson et al. 2005; van Landeghem
et al. 2001). GLT-1 uptakes glutamate into the microglial cell where it can be recycled by
glutamine synthetase (Aschner 2000; Chretien et al. 2002). Glutamate uptake and
degradation by glia would be neuroprotective by reducing the levels of glutamate in the
synapse (Gras et al. 2003).
Oxidative Stress
Microglia are both sources of ROS and are activated by increased ROS
production. CR3, previously discussed for its role in phagocytosis, has been shown to be
upregulated by ROS indicating that microglia activation is sensitive to oxidative stress
(Roy et al. 2008). Activated microglia can then be a source of ROS by releasing
superoxide, hydrogen peroxide, hydroxyl free radicals from NADPH oxidase phagocytic
reactions (Block et al. 2007; Reynolds et al. 2007). This release of ROS, like so many
other facets of microglia activation, is also directed by proinflammatory cytokines like
TNF-α (Smith et al. 2012). The role of microglia within oxidative stress further implicates
microglia activation as a potential source of neurodegeneration.
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Neurogenesis
The heterogeneity of microglial activation is reflected in its effects on
neurogenesis also (Kohman and Rhodes 2013; Morrens et al. 2012). The balance of
microglia-derived cytokines and growth factors can regulate of adult hippocampal
neurogenesis (Ekdahl et al. 2009). Specifically, the type of cytokines secreted by
microglia affects neurogenesis (Butovsky et al. 2006; Ekdahl et al. 2009). When fully or
classically activated, microglia secrete proinflammatory cytokines that are generally
associated with reductions in normal adult neurogenesis (Ekdahl et al. 2003; Monje et al.
2003). These reductions in neurogenesis can occur due to various effects on
neurogenesis. For example when interleukin 6 (IL-6), a proinflammatory cytokine, is
produced, it results in decreased proliferation (Vallieres et al. 2002); whereas other
proinflammatory cytokines such as interferon gamma (IFN-γ) can dysregulate
differentiation, changing the fate of newborn cells from neuronal to astrocytic (Walter et
al. 2011; Yong et al. 1991). On the other end of the continuum, microglial activation is
necessary for reactive neurogenesis in response to neuronal damage (Deboy et al.
2006; Wainwright et al. 2009). In an adrenalectomy model of reactive neurogenesis,
blocking transforming growth factor-beta (TGF-β) receptors reduced neurogenesis
(Battista et al. 2006) whereas increases in IL-10 enhanced neurogenesis (Kiyota et al.
2012).
As previously described, microglia have the propensity to affect various
mechanisms of alcohol-induced neurodegeneration as well as recovery. Figure 1.3
depicts the ways in which microglia could be involved in recovery mechanisms. The
complex nature of microglia makes understanding the characteristics of microglia
following ethanol exposure of distinct interest. This dissertation focuses on the pro- or
anti-inflammatory state of microglia as well as the initiation and duration of activation as
an indicator of its role in alcohol-induced damage and/or recovery.
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Figure 1.3 Potential roles of microglia in alcohol-induced damage and recovery

Figure 1.3 Examples of the duality of microglia in promoting recovery mechanisms
(green arrows) and contributing to neuronal damage (red arrows)

Alcohol & Neuroimmune System
Alcohol modulates the immune system of various organ systems including but
not limited to the respiratory, musculoskeletal, and digestive system. Whether alcohol is
an immunosuppressant or immunoactivating agent varies within each system (Molina et
al. 2010). The digestive system, specifically the liver has been a major focus of studies
examining the effects of alcohol on inflammation and the immune system. This focus is
mainly due to the common occurrence of liver cirrhosis in alcoholics (Beier and McClain
2010; Wang et al. 2012b). Studies looking at alcoholic liver cirrhosis have shown the
effects of alcohol on monocytes in the periphery. Monocytes isolated from the blood of
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alcoholics have greater basal expression of proinflammatory cytokines as well as react
more robustly to challenges with lipopolysaccharide (LPS; Barve et al. 2006; McClain
and Cohen 1989). The fact that microglia are the monocytes of the CNS suggests that
microglia likely would also be affected by chronic ethanol exposure.
Initially few studies examined microglia as it was originally proposed that alcoholinduced brain damage was too low and chronic to perturb microglia (Streit 1994).
However, recent trends have shown a marked increase in the literature exploring the
neuroimmune system in alcohol and drug abuse (Coller and Hutchinson 2012; Cui et al.
2011). The brains of human alcoholics have shown some indices of microglial activation.
Increases in the microglial secreted protein monocyte chemoattractant protein (MCP-1)
were seen in various regions of the mesolimbic pathway including the ventral tegmental
area, the substantia nigra, the amygdala, and importantly for this work, the hippocampus
(He and Crews 2008). As the name implies, MCP-1 is a chemokine that causes the
congregation of monocytes and T cells by initializing the motility of microglia/
macrophages (Carr et al. 1994; Hinojosa et al. 2011). Accompanying the increase in the
MCP-1 were increases in markers of microglia activation (He and Crews 2008).
However, neither microglial activation nor attraction by MCP-1 within an area is enough
to indicate a proinflammatory state nor causation between microglia activation and AUD
associated neurodegeneration (Hickey 2001; Hinojosa et al. 2011). These results
however do imply that chronic ethanol exposure affects the neuroimmune system.
Studies of postmortem brains of alcoholic agree with studies looking at microglial
activation that the neuroimmune system is altered within AUDs, but chronic alcohol
consumption causes dysregulation of the NF-κB system (Okvist et al. 2007). Chronic
ethanol exposure down regulated mRNA levels associated with the innate immune
system as well as decreased NF-κB binding to DNA within the prefrontal cortex (Liu et
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al. 2006; Okvist et al. 2007). While these studies done on the brains of postmortem
alcoholics do not agree on the direction of the effects of alcohol on potential
neuroinflammatory signaling, together, they indicate that chronic alcohol exposure
results in neuroadaptations that alter the normal neuroimmune function.
To truly appreciate alcohol’s modulatory effects on the neuroimmune system
requires AUD models. The vast majority of the work looking at alcohol’s influence on the
neuroimmune system has been done in vitro or in rodent models of AUDs examining the
effects of alcohol on immune gene responses, BBB disruption, astrocytic activation, and
finally microglial modulation. In vitro studies using organotypic hippocampal-entorhinal
cortex cultured brain slices and animal models have confirmed results seen in human
alcoholics showing modulation of the NF-κB system (Crews et al. 2006a; Zou and Crews
2010). However, these studies only show an upregulation of NF-κB as well as increased
binding (Crews et al. 2011; Zou and Crews 2010). This effect differs from observations in
the brains of human alcoholics where genes within the NF-κB were both up and down
regulated (Okvist et al. 2007; Zou and Crews 2010). The differences measured are not
surprising given the transient nature of many responses in the immune system including
NF-κB upregulation (Cechetto 2001). Many in vitro studies look at the effects of alcohol
on the neuroimmune system during ethanol exposure. However, alcohol abuse is driven
by phasic patterns of use including periods of intoxication, acute withdrawal, and
abstinence (Heilig et al. 2010). Studying the effects of the ethanol on the neuroimmune
system during these different periods gives a fuller view of how neuroinflammation may
be involved with damage. Moreover, AUD models, including the Majchrowicz model,
indicate that neurodegeneration can occur during intoxication and in abstinence making
studying neuroimmune changes in a timeline crucial.
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Disruption of the BBB is a major component of a neuroinflammatory response
(Hickey 2001). The increase in MCP-1 seen in the brains of post-mortem human
alcoholics is of interest not only due to its role in attracting glial cells but also because
MCP-1 is associated with the breakdown of the BBB (Stamatovic et al. 2003; Stamatovic
et al. 2005). However, despite increases in MCP-1, no direct evidence of BBB disruption
within human alcoholics exists. In vitro models using human epithelial cells to mimic the
BBB have found damage to the cells indicative of BBB disruption. In these models,
ethanol disrupts proteins associated with tight junctions as well as indirectly causes
endothelial cell through ROS production both of which can lead to BBB disruption
(Haorah et al. 2007a; Haorah et al. 2005; Haorah et al. 2007b). The integrity of the BBB
is vital to controlling inflammatory events and compromising it is just one more possible
cause of damage (Russo et al. 2011). The integrity of the BBB will be examined in
experiments presented in chapter two.
In vitro and in vivo models of AUD studies have consistently shown changes in
glial cells and their function in response to ethanol. Although the focus of this
dissertation is the effects of ethanol on microglia, astrocytes play a major role in
neuroimmune function and therefore cannot be ignored (Dong and Benveniste 2001).
Both in vitro and in vivo models have shown that astrocytes are affected by ethanol
exposure but results differ based on whether ethanol is present in the culture or animal,
respectively (DeVito et al. 2000; Franke et al. 1997; Kane et al. 1996; Kelso et al. 2011).
For example, during abstinence glial fibrillary acidic protein (GFAP), an
immunohistochemical marker of astrocytes, is upregulated indicating that astrocytes are
activated in recovery from ethanol (Hayes et al. 2013; Kelso et al. 2011), but in vitro
studies suggest that ethanol would inhibit the proliferation of astrocytes during
intoxication (Kane et al. 1996). Furthermore, ethanol’s effects on astrocytes have been
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implicated in other problems associated with chronic ethanol use that would affect the
neuroimmune system and/or mechanisms of neurodegeneration including disruptions of
the BBB (Abdul Muneer et al. 2011), glutamate excitotoxicity (Miguel-Hidalgo 2006; Wu
et al. 2011), and ROS production (Gonthier et al. 1997; Jin et al. 2013). The astrocytic
contribution to the neuroimmune reaction is important, but these studies focused on
microglia.
Alcohol & Neuroimmune System: Microglia Activation
Much like the effects of ethanol on astrocytes, various models of alcohol abuse
agree that microglia are activated following ethanol exposure (Kelso et al. 2011; McClain
et al. 2011; Ward et al. 2009a; Zhao et al. 2013), but the phenotype, initiation, and
duration of microglia activation within these models is not as clear. Some have
discussed microglial activation as initiating a neuroinflammatory response that leads to
neurodegeneration (Crews et al. 2011; He et al. 2005; Qin and Crews 2012a; Qin and
Crews 2012b; Qin et al. 2008). The majority of the “neuroinflammation driving AUD
neurodegeneration” studies looks at the neuroimmune response during intoxication and
do not consider immune response as a necessary function to restore homeostasis. The
duration and timing of microglial activation is just as important as the type of activation.
For example, the Crews lab has indicated that increases in TNF-α concentrations
following ethanol exposure maybe a causative factor in neurodegeneration (Crews et al.
2006b; Qin et al. 2008), but acute increases in proinflammatory cytokines can actually
promote neuroprotection (Song et al. 2013; Turrin and Rivest 2006). Furthermore,
studies in other models of alcohol-induced neurodegeneration have not observed
proinflammatory cytokines either during intoxication or in abstinence and suggest that
microglial activation may be involved with recovery (McClain et al. 2011; Zahr et al.
2010a). Similar to controversies regarding cytokines induced by ethanol exposure,
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some studies have described more classical signs activation of microglia looking at the
proteins expressed such as increases in MHC-II (Ward et al. 2009a) and phagocytic
activity (Zhao et al. 2013), while others have only seen evidence of low grade partial
activation (McClain et al. 2011; Nixon et al. 2008).
The level of activation is not the only point of contingency regarding ethanol’s
effect on microglia as the source of activation is not clear. Studies looking at astrocytic
and microglial cultures suggest that the toll like receptor 4 (TLR4) cell signaling cascade
can be directly induced by ethanol (Blanco et al. 2005; Fernandez-Lizarbe et al. 2013;
Fernandez-Lizarbe et al. 2009). It has been proposed that ethanol modulates TLR4
signaling by modulating lipids within the cell membrane of glial cells (Blanco et al. 2008;
Fernandez-Lizarbe et al. 2013; Fernandez-Lizarbe et al. 2008). Direct ethanol induction
of TLR4 signaling would suggest that microglia activation is the result of an inflammatory
response of astrocytes. However, others using in vivo models suggest that microglial
and astrocytic activation occurs as a result of neuronal damage and is subsequent to
neurodegeneration (Kelso et al. 2011; McClain et al. 2011). The chronological order of
events indirectly implies causation and is a crucial aspect of understanding the role of
microglial activation within AUDs. If microglia are activated prior to neurodegeneration, it
implies that the neuroimmune response may mediate neuronal damage. However, if
microglia activation is a consequence of damaged cells, the neuroimmune response
may initiate as a recovery mechanism. Both the type of microglial activation and the
chronology of evidence of activation and degeneration will be determined in experiments
presented in chapters two and three.
Alcohol & Neuroimmune System: Microglial Priming
One of the key contributing factors of the theory that chronic alcohol consumption
causes neurodegeneration through a microglial associated neuroinflammatory response
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is that the microglial response is exacerbated or perpetuated by influences from the
systemic system (Crews 2012; Cunningham 2013; de la Monte et al. 2009). The basic
premise of this theory is that chronic ethanol exposure disrupts the BBB and allows the
infiltration of peripheral immunomodulators such as activated peripheral macrophages
and their associated cytokines that then alter microglia activation and the neuroimmune
signaling (Crews 2012; Crews et al. 2011). Studies have shown that persistent activation
of microglia following an initial damaging event can impact the neuroimmune system by
modulating secondary or future microglial responses to other immune challenges (Dilger
and Johnson 2008; Norden and Godbout 2013). This phenomenon has been referred to
as microglial priming and has been shown to affect the neuroimmune response for
extended periods. Primed microglia exhibit a more robust proinflammatory response
upon secondary activation. For instance, early-life infection in rodents caused microglial
to be activated (Bilbo and Schwarz 2009). This microglial activation persisted into
adulthood to a lower degree than the initial adolescent response; however, upon
subsequent immunological challenge, primed microglia produced higher levels of
proinflammatory cytokines compared with microglia from rodents without an early life
infection. This exacerbated response months after the initial damaging event resulted in
deficits in neurogenesis as well as cognition (Bilbo and Schwarz 2009; Bland et al. 2010;
Williamson et al. 2011). In support of this phenomenon in AUDs, studies show that prior
ethanol exposure exacerbates the microglial response to LPS and
polyinosinic:polycytidylic acid (Poly IC; Qin and Crews 2012a; Qin et al. 2008). Both LPS
and Poly IC at the doses used produce a robust immune response, which complicates
the interpretation of these studies (Qin and Crews 2012a; Qin et al. 2008). In chapter
four, the ability of ethanol alone to act as a “secondary hit” to a primed response will be
considered. Determining if ethanol alone exacerbates microglia activation is important as
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alcohol-induced neurodegeneration is seen independent of liver cirrhosis, the
hypothesized source of systemic inflammation (Harper and Matsumoto 2005; Zahr et al.
2009).
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Project Overview
Neuroplastic changes that occur from chronic alcohol consumption are one potential
underlying event in the progression of an AUD. One such neuronal consequence is
neurodegeneration in the corticolimbic pathway. Understanding the mechanisms that
lead to neuronal damage may partially shed light on the progression of AUD
development. The current dissertation examines neuroinflammation as a potential
mechanism of alcohol-induced neurodegeneration, specifically by investigating the
effects of ethanol on microglia. A rat model of an AUD known to cause
neurodegeneration was used to determine the phenotype and persistence of microglia
activation from varying durations of ethanol exposure. The overarching hypothesis for
this project is that alcohol exposure elicits a differential response on microglia
depending on the duration of ethanol exposure as well as whether activation is
measured during intoxication or abstinence.

Aim 1: Determine the phenotype of microglia reactivity following binge ethanol exposure
(Chapter 2).
We hypothesize that binge ethanol exposure induces low-grade, partial microglia
activation. The phenotype of activation will be determined following ethanol exposure
examining proteins expressed within microglia using autoradiography and
immunohistochemistry to examine. The microglial phenotype will also be assessed using
ELISAs to look at cytokine expression.

Aim 2. Determine the earliest indices of microglial activation in the Majchrowicz model of
an AUD (Chapter 3).
We hypothesize that the initial microglial response will occur subsequent to days
of ethanol exposure previously shown to cause neurodegeneration. [3H]-PK-11195, a
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sensitive microglial activation marker, will be used to determine the earliest indices of
microglial activation, and microglial cell counts will be used to ensure that measurements
of [3H]-PK-11195 are based on activation and not changes in cell number.

Aim 3. Determine if alcohol-induced microglia reactivity following the Majchrowicz model
is “primed” (Chapter 4).
We hypothesize that a second binge ethanol exposure will potentiate the
microglia response seen after binge ethanol exposure and produce classical signs of
activation. Microglial activation phenotype will be determined following a second ethanol
exposure using immunohistochemistry to look at the markers indicative of pro- versus
anti-inflammation, whereas ELISAs will be used to assess function by looking at cytokine
expression.
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Chapter 2: Microglial activation is not equivalent to neuroinflammation in alcoholinduced neurodegeneration: the importance of microglia phenotype
INTRODUCTION
Whether microglial activation is the cause or consequence of neurodegeneration
is a hotly debated topic in studies of neurodegenerative disease. Although not
traditionally classified as a neurodegenerative disease due to its preventable nature,
AUDs and specifically the characteristic excessive consumption of alcohol, result in
corticolimbic neurodegeneration that underlies a variety of cognitive deficits in alcoholics
(Crews and Nixon 2009; Obernier et al. 2002a; Pfefferbaum et al. 1992; Sullivan et al.
1995). As alcohol-induced neurodegeneration is thought to be a critical step in the
development of an AUD (Crews and Boettiger 2009; Crews et al. 1999; Koob and Le
Moal 1997), understanding how excessive alcohol consumption results in neuronal loss
is crucial for the development of prevention and treatment strategies. It has been
hypothesized that alcohol-induced neuroinflammation directly contributes to
neurodegeneration and the development of AUDs (Crews et al. 2011).
Neuroinflammation has been inferred from the upregulation of a variety of
proinflammatory genes and cytokines involved in the innate immune system (Crews et
al. 2006b; He and Crews 2008; Knapp and Crews 1999; Qin et al. 2008). For example,
chronic ethanol exposure induces innate immune signaling cascades through activation
of the proinflammatory transcription factor, NF-κB (Crews et al. 2006b; Crews et al.
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2011; Valles et al. 2004). Others have shown that a variety of proinflammatory signals
are associated with increased ethanol drinking and preference (Blednov et al. 2012) and
that peripheral inflammation promotes increases in voluntary ethanol intake whereas
anti-inflammatory administration reduces its consumption (Agrawal et al. 2011; Blednov
et al. 2011). However, remarkably little is known about the effects of alcohol on
microglia, the primary mediators of the innate immune system in the brain.
Microglial activation, the process in which microglia alter their morphology and
functionally differentiate in response to changes in their environment, was traditionally
described as proinflammatory and cytotoxic (Kreutzberg 1996). In normal, nonpathologic conditions microglia are generally in a quiescent state often referred to as
“resting.” Quiescent microglia, however, are not truly resting; their highly ramified
morphology reflects their constant surveying of the surrounding environment (Fishman
and Savitt 1989; Nimmerjahn et al. 2005). For many neurodegenerative disorders,
activated microglia are a hallmark of neuroinflammation (Banati et al. 1993; Block and
Hong 2005; Colton and Gilbert 1987; Woodroofe et al. 1991). However, more recent
work demonstrates that it is not just whether microglia are activated, but more
importantly their phenotype during activation (Carson et al. 2007; Colton and Wilcock
2010; Kreutzberg 1996; Raivich et al. 1999b). Various terms have been used to
describe a perceived dichotomy in microglial phenotype including M1 versus M2,
classical versus alternative and classical versus partial activation. However, all classify
microglia into one of two categories when it is a spectrum of phenotypes or behaviors
that exist. For example, microglia phenotype varies with the type of insult, the extent of
damage, and the time of recovery post injury, which makes it necessary to thoroughly
examine phenotypic hallmarks within a disease before inferring their role in
neuroinflammation (Harting et al. 2008; Lai and Todd 2008; Saijo and Glass 2012).
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Application of the idea of graded levels of activation allows for investigation of a potential
spectrum of phenotypes. As such, Raivich defines 5 levels of microglial activation or
phenotypes (Table 2.1): resting (stage 0), alert (stage 1), homing (stage 2), phagocytic
(stage 3a) and bystander activation (stage 3b), which can be differentiated by both
morphology and cytokine and/or growth factor upregulation (Raivich et al. 1999a). For
example, amoeboid morphology and expression of proinflammatory factors such as
TNF-, IL-1ß, prostaglandins, superoxides and nitric oxide, characterize the highest
level of activation whereas microglia in lower grades of activation release
neuroprotective factors such as IL-10, TGF-ß, and neurotrophins and have a more
ramified morphology (Block and Hong 2005; Raivich et al. 1999b). Furthermore,
although fully activated microglia are one component of classical inflammation,
observation of “activated” microglia alone is not equivalent to nor very informative about
the inflammation state (Graeber et al. 2011). Therefore, determining the phenotype of
microglia in injury is necessary to understand their role as cytotoxic or neuroprotective
and whether they are truly neuroinflammatory (Colton and Wilcock 2010; Kreutzberg
1996; Vilhardt 2005).
A role for cytotoxic microglia in alcohol-induced brain damage has been
suggested since the 1990s, however direct evidence of alcohol-induced full or classical
microglia activation has yet to be described. The lack of classical signs of activation led
some to suggest that the damage in alcoholism is “too chronic” (Streit 1994) or too low
level to affect microglia (Kalehua et al. 1992); however, there is evidence of some level
of activation in both animal models and human postmortem alcoholic brain. For
example, early work showed an upregulation in the microglial marker, [3H]-PK-11195,
binding months after alcohol exposure in a four-day binge model of alcoholic
neurodegeneration (Obernier et al. 2002b). Later, an unexpected discovery of microglial
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proliferation was found in this same model (Nixon et al. 2008). More recently,
upregulation of various microglial markers have been described in animal models
(McClain et al. 2011), and even led some to conclude that excessive alcohol exposure
produces “neuroinflammation” (Qin et al. 2008; Ward et al. 2009b). Importantly,
although evidence of microglial activation has been observed in human alcoholic brain
samples, the phenotype of these alcohol-activated microglia has yet to be described
(Crews et al. 2006b; Crews et al. 2011; He and Crews 2008). Unfortunately, the
pervasive theme of these and other papers is that the observation of any marker of
activation is equivalent to neuroinflammation. The assessment of single markers of
activation is not sufficient to characterize the activation phenotype of microglia and as
discussed above, not indicative of inflammation (Colton and Wilcock 2010).
Table 2.1 Microglia Heterogeneity
Microglial
Morphology and Markers
Cytokines
Characteristics
Stage 0 Normal-Ramified
Morphology: long ramified processes
Stage 1 Alert: thicker
Less ramified, thicker processes; OX-42 TGF-ß1
processes
Stage 2 Homing, Proliferation Bushy; Proliferation markers
IL-10
Stage 3a Clustered phagocytes Amoeboid; possible MHC-I, ED-1
IL-6, TNF-α
(CD68)
Stage 3b Bystander activation; MHC-I, Lower ICAM than 3a
IFN-
Lymphocyte binding
Table 2.1 Microglial activation can be differentiated based on morphology and marker
expression (derived from Raivich et al., 1999a). The cytokines denoted are indicative of
a change in expression. For example, microglia characterized as 3a will still express IL10 but in addition will secrete proinflammatory cytokines such as IL-6 at higher
concentrations. An immune response can occur independent of activation and may be
observed in Stages 1 – 3 as evidenced by increased MHC-II (OX-6).

The current experiments examine how ethanol exposure, in a well-established
model of an AUD that includes significant alcohol-induced neurodegeneration, affects
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microglia within the context of classical definitions of inflammation. Specifically,
inflammation is defined as a “multicellular process characterized by changes in the
vasculature and infiltration of mobile cells.” (p. 3800; Graeber et al., 2011). This study
uses an extensive assessment of immunohistochemical, morphological, and functional
indices of microglial activation in order to determine their phenotype in the hippocampus
and entorhinal cortex, regions consistently damaged in this binge paradigm (Collins et al.
1996; Obernier et al. 2002a). Alcohol’s effect on the integrity of the BBB was also
examined, as macrophage and/or lymphocyte infiltration is a defining phenomenon in
inflammation (Hickey 2001).

MATERIALS AND METHODS
Alcohol Administration Model
Rats were subjected to a four-day binge model of alcohol exposure modified from
Majchrowicz (1975). This model is designed to mimic the high blood alcohol levels of
pattern binge drinkers (Hunt 1993; Tomsovic 1974) and was chosen for its welldocumented neurodegeneration profile (Crews 1999; Kelso et al. 2011). All procedures
performed were in accordance with the University of Kentucky Institutional Animal Care
and Use Committee and aligned with the Guidelines for the Care and Use of Laboratory
Animals (NRC, 1996). A total of 214 adult male Sprague-Dawley rats (Charles River
Laboratories, Raleigh, NC) were used across all experiments. Animals were 275-300g
upon arrival and single-housed in a University of Kentucky AALAC accredited vivarium
with a 12h light:dark cycle and had ad libitum food and water access unless otherwise
noted. Rats were allowed to acclimate to the vivarium for five days but were handled for
three days before the binge began to reduce anxiety associated with handling.
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Rats were divided into two groups of comparable weights and received either
ethanol (25% w/v) or control diet (isocaloric amounts of dextrose) in Vanilla Ensure
Plus®. Diet was given every 8h for 4 days via intragastric gavage. During the four days
of diet administration, chow was removed and returned 8h after the last dose. Initially,
each rat received a 5g/kg dose of ethanol with subsequent doses titrated based on
intoxication behavior according to a 6-point scale modified from Majchrowicz (1975) but
identical to previously published methods (Morris et al., 2010b; Nixon and Crews, 2004).
For example, an animal that simply seems ataxic would receive more ethanol than one
that who has lost its righting reflex (Table 2.2). Ethanol animals with intoxication scores
of four or greater were given 2mL of water to avoid dehydration. Control animals
received the average volume given to the ethanol group to control for neuroplastic
changes associated with caloric intake (Gillette-Guyonnet and Vellas 2008; LoncarevicVasiljkovic et al. 2012).
Table 2.2 Intoxication Scale
Intoxication Score
Behavioral Attributes
Ethanol Dose (g/kg)
0
Normal animal
5
1
Hypoactive, mildly ataxic
4
2
Ataxic, elevated abdomen
3
Ataxic, absence of abdominal elevation,
3
2
delayed righting reflex
Loss of righting reflex, retain eye blink
4
1
reflex
Loss of righting reflex, loss of eye blink
5
0
reflex
Table 2.2 Animals CNS depression (intoxication) was scored based on behavioral
attributes to determine the appropriate ethanol dose.
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Ninety minutes after the seventh session of ethanol dosing, tail blood samples
were collected. This time point represents the peak intoxication profiles from intragastric
gavage studies in rats (Kelly et al. 1987; Livy et al. 2003). Samples were centrifuged for
5 min at 1800g to separate plasma from red blood cells and stored at -20˚C to avoid
sample degradation. BECs were determined from 5μL of supernatant serum using an
AM1 Alcohol Analyser (Analox, London, UK). Each sample was run in triplicates
calibrated against a 300mg/dL external standard and the average expressed as mg/dL.
The AM1 Alcohol Analyser works by measuring the oxygen consumption in the oxidation
of alcohol to acetaldehyde and hydrogen peroxide (Analox 2007).
Ten hours following the last dose of ethanol, withdrawal was observed for 30
minutes every hour for 16 intervals. Withdrawal behaviors were scored based on a
scale modified from Majchrowicz (Majchrowicz 1975; Penland et al. 2001) but identical
to that reported previously (Table 2.3; Morris et al., 2010b). Because microglia respond
quickly to changes in homeostasis (Davalos et al., 2005; Nimmerjahn et al., 2005) but
also have the capacity for persisting memory (Bilbo and Schwarz, 2009; Bland et al.,
2010; Williamson et al., 2011) this study examines microglial changes immediately
following ethanol exposure through 28 days of abstinence. Therefore, rats were
euthanized at various timepoints within this range following binge treatment: T0 (e.g. 0
days after the last dose, specifically within hours), T1, T2, T4, T7, and T28.
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Table 2.3 Withdrawal Scale
Withdrawal Score
Behavioral Attribute
1.0
Hyperactivity
1.4
Tail Tremor
1.6
Tail Spasm
2.0
Caudal Tremor
2.2
Tip Toe Arch
2.4
Splayed Limbs
2.6
General Tremor
3.0
Head Tremor
3.2
Induced Running
3.4
Wet Dog Shakes
3.6
Chattering teeth
3.8
Spontaneous Convulsions
4.0
Death
Table 2.3 Animals’ behavior was scored based on a modified scale of withdrawal
symptoms (Majchrowicz, 1975; Penland et al., 2001).
Autoradiography
Autoradiography was conducted as described in previous reports (Kelso et al.,
2006; Sparks and Pauly, 1999). Rats were rapidly decapitated and extracted brains
were immediately frozen in isopentane and sliced at 16µm with a cryostat. Two controls
were euthanized at each time point and pooled into a single control group for
comparison with ethanol treated groups (Readnower et al., 2010). Sections were
mounted in a 1 in 8 series on glass slides so that every eighth section was used and
stored at -80˚C until processing. Slides were thawed and incubated in 50mM Tris HCl
(pH=7.4) buffer with 1nM [3H]-PK-11195 (PerkinElmer, Boston, MA) for 2h followed by a
series of washes in 50mM Tris HCl. [3H]-PK11195 specifically binds to the mitochondrial
translocator protein 18kDa (TSPO), a protein that is highly upregulated in activated
microglia and is associated with cholesterol transport (Kelso et al. 2009; Stephenson et
al. 1995; Veiga et al. 2007). Similar to other studies of microglial activation after brain
insult, autoradiographic localization of TSPO was used in this study because of its high
sensitivity to detect activated microglia (Benavides et al. 2001; Readnower et al. 2010).
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After drying, the slides were exposed to BioMax film (Kodak, Rochester, NY) for
6 weeks. The film was developed with GBX developer (Kodak) and analyzed using
ImageJ (Scion Imaging; Frederick, Maryland) to determine the relative binding levels by
optical density. Sections between approximately between Bregma -2.50mm and 4.00mm, which included both the hippocampus and entorhinal cortex, were quantified
(Paxinos and Watson, 2009).
Immunohistochemistry
Rats were overdosed with anesthetic (Nembutal® 100mg/kg; ip) and
transcardially perfused with 0.1M phosphate buffered saline (PBS, pH=7.4) followed by
4% paraformaldehyde in PBS. Brains were extracted, postfixed in paraformaldehyde for
24 hours (ED-1, OX-6, Iba-1, and IgG) or 1 hour (OX-42), and sectioned coronally at
40µm using a vibrating microtome (Leica VT1000S; Wetzlar, Germany). Sections were
collected in a 1:12 series and stored in cryoprotectant at -20˚C until processing so that
every twelfth section was stained for each antibody of interest. Free floating tissue was
washed in tris buffered saline (TBS, pH=7.5) and endogenous peroxidases quenched
with 0.6% H2O2 in TBS. Following additional washes, sections were blocked for
nonspecific binding (TBS, 0.1% triton X-100, and 3% horse or goat serum), and then
incubated overnight in primary antibody at 4˚C as follows: mouse anti-OX-6 (1:500,
Serotec, Raleigh, NC), mouse anti-ED-1 (1:500; Serotec), rabbit anti-Iba-1 (1:1000,
Wako, Richmond, VA), or mouse anti-OX-42 (1:1000; Serotec)
Primaries were chosen for their specificity for activated microglia phenotypes
(Table 2.1). The Iba-1 antibody recognizes a 17kDa EF hand protein that is similar in
structure to other calcium binding proteins such as calmodulin (Heizmann and Hunziker
1991; Imai et al. 1996; Ito et al. 1998). Iba-1 is used to mark all microglia, but it is
upregulated during activation as it is associated with the release of cytokines, adhesion,
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and proliferation (Donato 1999; Donato 2003; Hwang et al. 2006). The OX-42 antibody
is also constitutively expressed in all macrophages and recognizes CR3 or CD11b
(Robinson et al., 1986). Upregulation of this receptor is one of the first indices of
activation as microglia prepare to adhere to damaged cells (Hynes, 1992; Morioka et al.,
1992). Unlike Iba-1 and OX-42, ED-1 and OX-6 are not expressed in all microglia. The
ED-1 antibody, also known as anti-CD68, recognizes a glycoprotein on the lysosomal
membrane of macrophages and microglia that is indicative of phagocytic activity (Bauer
et al., 1994; Damoiseaux et al., 1994). ED-1 is typically used to determine the presence
of classically or fully activated phagocytic microglia (Graeber and Streit 2009; O'Keefe et
al. 2002; Raivich et al. 1999a). The OX-6 antibody recognizes MHC-II associated with
induction of T-helper cells (O'Keefe et al., 2002; Raivich et al., 1999a). Although OX-6 is
also associated with the recruitment of phagocytes and is considered a hallmark of an
immune response (Kaur and Ling 1992; McGeer et al. 1993), recent work suggests that
it may also be expressed in partially activated microglia (Colton and Wilcock, 2010).
Microglia exhibit weak antigen-presenting capabilities, but many neuroinflammatory
reactions involve the upregulation of microglial MHC-II (Zhang et al. 2011).
Methods for the application of secondary antibody (biotinylated horse antimouse, rat adsorbed, or biotinylated goat anti-rabbit, Vector Laboratories, Burlingame,
CA), avidin-biotin-peroxidase complex (ABC Elite Kit, Vector Laboratories) and
chromagen, nickel-enhanced 3,3’-diaminobenzidine tetrahydrochloride (DAB;
Polysciences, Warrington, PA), were identical for all primary antibodies and followed
previously published methods (McClain et al., 2011).
To determine if infiltration of macrophages and lymphocytes could occur in this
model, BBB impairment was examined. Tissue was incubated in biotinylated rabbit antirat IgG for 2 hours followed by detection with ABC and the chromagen DAB
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(Rabchevsky et al. 1999; Schmidt-Kastner et al. 1993). The IgG antibody is a marker of
immunoglobulin G. With an intact BBB, immunoglobulins would remain in the peripheral
system due to a lack of transport mechanisms (Triguero et al. 1989); thus, the presence
of IgG in the brain parenchyma indicates BBB disruption. Following the final wash, all
stained sections were mounted onto glass slides and dried before being coverslipped
with Cytoseal® (Stephens Scientific, Wayne, NJ).
Quantification
All sections were coded to ensure the experimenter was blinded to treatment
conditions during quantification. All analyses were conducted on an Olympus BX-51
microscope (Olympus, Center Valley, PA), with motorized stage (Prior, Rockland, MA),
microcator and DP70 digital camera (Olympus). OX-42 immunoreactivity was analyzed
using Visiomorph image analysis program (Visiomorph, Hørsholm, Denmark). Using a
10x objective lens, regions of interest were drawn around the hippocampal subregions
and the entorhinal cortex approximately between Bregma -2.50mm and -4.00mm as
determined by Paxinos (Paxinos and Watson, 2009). Immunoreactivity was determined
by optical density and the percent area of staining was obtained. Images were run in a
batch process, and immunoreactivity was calculated and expressed as percent control.
Sections in the same stereotaxic regions were assessed qualitatively for the presence of
ED-1, OX-6 and IgG using a 10x objective.
Iba-1+ cells were quantified in the entorhinal cortex by an image analysis system.
Multi-panel images containing the entire entorhinal cortex were collected using
Visiopharm image capturing software approximately between Bregma -2.30mm and 4.50mm (Paxinos and Watson, 2009). For each image, the number of Iba-1+ cells was
determined by Image Pro Plus software based upon both the size and immunoreactivity.
This program has been shown to be comparable to the alternative method of visual
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counts when immunoreactive cells are distinct from background (Francisco et al. 2004).
The number of cells per section was averaged and expressed as Iba-1+ cells/section.
Hippocampal Iba-1+ cells were estimated by unbiased stereological methods, the
optical fractionator, using the newCAST Stereology System (Visiopharm, Hoersholm,
Denmark) installed on a Dell Precision 380 workstation coupled to the microscope.
Following parameters similar to previous reports (Long et al. 1998), the DG, cornu
amonis(CA)2/3, and CA1 regions of the dorsal hippocampus approximately between
Bregma -2.30mm and -4.50mm as determined by Paxinos (Paxinos and Watson, 2009)
were separately traced at 100x magnification. Section thickness was assessed at 600x
using a 60x oil immersion lens and was averaged from three measurements taken at
different locations within each region. The DG and CA2/3 were randomly sampled using
a 70µm x 70µm counting frame with a 250µm x,y step length. The CA1 was randomly
sampled using the same size counting frame and a 400µm x,y step length. After tissue
processing, section thickness was approximately 24 µm, therefore, a dissector height of
20um with 2µm guard zones. Total Iba-1+ microglia in each region of interest was
calculated using the following equation (West et al., 1991):

where Q is the number of cells counted, asf is the area sampling fraction (the counting
frame: x,y step length ratio), tsf is the thickness sampling fraction (dissector height:
section thickness ratio), and ssf is the section sampling fraction (the fraction of sections
examined). For all stereological quantifications, coefficient of error ranged from 0.008 to
0.039 and averaged 0.021 ± 0.001. A coefficient of error less than 0.05 is considered
adequate (Gundersen et al. 1999).
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Enzyme Linked Immunosorbent Assay
Rats were rapidly decapitated and the brain immediately extracted. The
hippocampus and entorhinal cortex were dissected on ice, snap frozen on dry ice, and
stored at -80˚C until assayed. Thawed tissue was manually homogenized in an ice-cold
lysis buffer (1mL of buffer/50mg of tissue; pH=7.4). All reagents used in the lysis buffer
were purchased from Sigma (St. Louis, MO) unless otherwise noted. It consisted of
25mM HEPES, 0.1% 3-[(3-cholamidopropyl) dimethyl-ammonio]1-propanesulfonate,
1.3mM EDTA, 1mM EGTA, 10 µg/ml aprotinin, 10µg/ml leupeptin, 5mM MgCl2 (Fisher,
Fairlawn, New Jersey), 10 µg/ml pepstatin (Fluka, Milwaukee, WI), and 1mM PMSF
(Fluka; Rabuffetti et al., 2000). Homogenates were centrifuged at 20,000 x g for 15
minutes at 4oC and the supernatant stored at -80˚C. Total protein content was
determined using a Pierce BCA Protein Assay Kit (Thermo Scientific, Rockford, IL).
Cytokine protein content was determined with an ELISA kit according to the
manufacturer’s instructions for rat TNF- (Invitrogen product #KRC3011C, Camarillo,
CA), IL-10 (Invitrogen product #KRC0101), IL-6 (R&D Systems product #R6000B,
Minneapolis, MN), or TGF-β (Invitrogen product #KAC1688). All samples, standards,
and positive controls were run in duplicate so that all tissue for one time point fit on one
plate to reduce potential variability. Absorbance was measured at 450nm on a DXT880
Multimode Detector plate reader (Beckman Coulter, Brea, CA).The cytokine protein
concentration was divided by the total protein concentration obtained in the BCA assay
to correct for differences in tissue volume. Protein concentration is reported as pg of
cytokine/ mg of protein.
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Statistical Analyses
Data were analyzed and graphed using Prism Version 5.04 (GraphPad Software,
Inc. La Jolla, Ca). All data are reported as the mean ± standard error of the mean and
analyses considered significantly different if p<0.05. Behavioral scores were analyzed
with a Kruskal Wallis test and BECs, autoradiography, OX-42, cytokine expression, and
cell counts were analyzed by ANOVA with post-hoc tests as appropriate. Each region of
the hippocampus or entorhinal cortex is considered independent and therefore was
analyzed separately.

RESULTS
Animal Model Data
Intoxication parameters across all experiments were similar as shown in Table
2.4. The overall mean intoxication score for all ethanol animals was 1.9 ± 0.1 on the 6point Majchrowicz scale, which indicates that all animals were, on average, “ataxic”
immediately before dosing. This level of intoxication resulted in an overall mean dose of
9.2 ± 0.3 g/kg/day of ethanol and a BEC of 354.0 ± 7.5 mg/dL for all animals used.
These parameters are similar to those reported in past studies with this model (Morris et
al., 2010a; Nixon and Crews, 2004) and similar to that observed in voluntary
consumption (Bell et al. 2009). Neither the Kruskal – Wallis (intoxication behavior) nor
one-way ANOVAs (dose, BEC) showed differences in any intoxication parameter
between ethanol groups at different time points.
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Table 2.4 Experiment One Animal Model Data
Experiment
Intoxication
Dose
BEC
Group
behavior
(g/kg/day)
(mg/dl)
(0–5 scale)
Autoradiography
T0 (n=6)
1.8 ± 0.3
9.7 ± 1.3
318.0 ± 14.5
T2 (n=6)
1.8 ± 0.3
9.8 ± 1.4
304.8 ± 18.4
T4 (n=6)
1.8 ± 0.3
9.4 ± 1.6
336.2 ±19.7
T7 (n=6)
1.8 ± 0.3
9.7 ± 1.4
345.1 ± 25.5
Immunohistochemistry T0 (n=7-8)
2.0 ± 0.3
9.1 ±1.2
361.5 ± 17.2
T2 (n=6)
1.9 ± 0.3
8.8 ± 1.5
286.7 ± 25.1
T4 (n=6)
1.7 ± 0.3
9.3 ± 1.5
**
T7 (n=7)
1.7 ± 0.2
9.8 ± 1.3
365.8 ± 36.4
T28 (n=7-8)
2.0 ± 0.3
9.1 ± 1.6
332.9 ±26.0
ELISA
T0 (n=8)
1.9 ± 0.3
9.3 ± 0.9
331.3 ±23.3
T1 (n=8)
2.1 ± 0.3
8.6 ± 1.3
401.5 ± 20.3
T2 (n=7)
2.1 ± 0.3
8.8 ± 1.3
411.3 ± 14.5
T4 (n=7)
2.2 ± 0.3
8.3 ± 1.6
400.5 ± 33.8
T7 (n=7)
2.3 ± 0.3
8.3 ± 1.7
365.8 ± 36.4
Table 2.4 Measures of various Intoxication parameters of the Majchrowicz model are
statistically similar between time points among all experiments. **BECs from this group
are omitted due to Analox malfunction but commonalities between behavioral
intoxication measurement and dose suggest that the BECs should be comparable.
[3H]-PK-11195 autoradiography reveals early activation of microglia
Binding of the TSPO ligand, [3H]-PK-11195, was measured by optical density at
T0, T2, T4, and T7. Control levels of binding at each time point were not statistically
different and therefore were pooled into a single control group (Readnower et al., 2010).
As shown in representative images, ethanol treated animals have increased binding
throughout the brain compared with controls (Figure 2.1). Specifically, one way
ANOVAs showed a significant main effect of diet in each region of the hippocampus:
CA1 [F(4,27) =14.93, p<0.0001], CA2/3 [F(4,27) =14.93, p<0.0001], and DG [F(4,27) =12.88,
p<0.0001], as well as in entorhinal cortex [F(4,27) =9.08, p<0.0001]. Post-hoc Tukey’s
tests confirmed a significant increase (p<0.05) in the density of [3H]-PK-11195 binding in
each ethanol treated time point compared to controls in all regions examined (Figure
2.1).
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Figure 2.1 Increased [3H]-PK-11195 following EtOH Exposure

Figure 2.1. [3H]-PK-11195 upregulation following 4-day binge exposure. Representative
false color autoradiographs depicting [3H]-PK-11195 binding are shown for (A) controls
(n = 8; black bars) as well as (B) ethanol (grey bars) at T0 (n = 6), (C) T2 (n = 6), and (D)
T7 (n = 6). The legend in the top right corner shows how the false color reflects the
intensity of binding. Quantitative analysis of the extent of binding are graphed for the (E)
CA1, (F) CA2/3, (G) DG, and (H) entorhinal cortex. *p < 0.05.
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Immunohistochemical markers of microglia indicate partial activation phenotype
In order to see the earliest signs of activation, we examined OX-42 expression
immediately after the last dose of alcohol (T0; rats are still intoxicated) and in a separate
group after four weeks of abstinence (T28). OX-42 positive cells were apparent in both
ethanol and control tissue which is consistent with its constitutive expression (Akiyama
and McGeer, 1990). However, there was a visibly distinct increase in immunoreactivity
at T0, reflecting a reduction in the ramification but a thickening of the processes in the
ethanol animals compared with the controls (Figure 2.2). Two-way ANOVAs indicated a
significant interaction between treatment and time point in the CA1 [F(1,25) =5.81,
p=0.0236], CA2/3 [F(1,26) =5.71, p=0.0244] DG [F(1,25) =5.90, p=0.0227] fields, as well as
in entorhinal cortex [F(1,25) =4.65, p=0.0409]. Planned post-hoc t-tests indicated a
significant increase after ethanol exposure in all regions at T0: CA1 [t(12) =2.39,
p=0.0345], CA2/3 [t(12) =2.23, p=0.0453], DG [t(12) =2.35, p=0.0367] and entorhinal cortex
[t(12) =2.21, p=0.0472]. Although the contrast between ethanol and controls was not as
distinct at T28, ethanol animals maintained a significant increase compared with controls
in all regions except the DG: CA1 [t(13) =2.45, p=0.0288], CA2/3 [t(13) =2.25, p=0.0427],
and entorhinal cortex [t(13) =4.80, p=0.0003].
The ED-1 antibody was used to recognize phagocytic microglia (Graeber and
Streit, 2009), whereas the OX-6 antibody was used to visualize the upregulation of
MHC-II. Neither ethanol nor control animals had ED-1 nor OX-6 positive cells within the
parenchyma of the hippocampus or entorhinal cortex at T0, T2, T4, T7, or T28 (Figure
2.3). However, ED-1 and OX-6 positive cells were visible in blood vessels and along the
meninges in both control and ethanol treated animals (Figure 2.3), similar to that
previously reported in this model (McClain et al., 2011; Nixon et al., 2008). Thus, fourday ethanol treatment failed to induce phagocytic-stage microglia or increased MHC-II in
the brain parenchyma at any time point.
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Figure 2.2 CD11b (OX-42) upregulation following 4-day binge exposure.

Figure 2.2. CD11b is upregulated in the hippocampus and entorhinal cortex at T0 as
shown in representative photomicrographs in rats exposed to binge (C, F) ethanol (T0:
n = 8; T28: n = 8; grey bars) compared to (A, E) controls (T0: n = 7; T28: n = 7; black
bars). Higher magnification of microglia seen in the hippocampus is shown for both (H)
control and (I) ethanol. Quantifications of OX-42 immunoreactivity for the subregions of
the hippocampus were significantly different: (B) CA1, (D), CA2/3, and (G) DG as well as
the (J) entorhinal cortex. Scale bar in C = 500 μm; F = 300 μm; J = 10 μm. *p < 0.05.
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Figure 2.3 No OX-6 or ED-1 Positive Microglia

Figure 2.3. ED-1 was not visible in the (A–D) hippocampus or (E–H) entorhinal cortex as
seen in representative photomicrographs for (A, E) controls (T2: n = 7; T7: n = 8) or (B,
C, F, G) ethanol (T2: n = 6;T7: n = 7) rats. No OX-6 positive cells were visualized in the
(I-K) hippocampus or (M-O) entorhinal cortex as seen in representative images for (I, M)
controls or ethanol rats at (J,K, N, O. Phagocytic and immune responsive macrophages
were visible in the blood vessels as seen in insets of (C) ED-1 and (J) OX-6,
respectively. ED-1 and immunopositive cells were visible in the (D, H, L, P) positive
control tissue from a rat treated with kainic acid. RF = rhinal fissure. Scale bar = 150 μm.
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Microglia proliferation results in increased number
We have previously shown that microglia proliferate two days after a four-day
alcohol binge (McClain et al., 2011; Nixon et al., 2008); therefore stereological estimates
of Iba-1-positive microglia were conducted at seven (T7) and twenty eight (T28) days
following the last ethanol dose in the hippocampus. The total number of microglia was
increased in the hippocampus of ethanol treated animals compared with controls seven
days after ethanol exposure (T7; Figure 2.4). Two-way ANOVAs indicated a significant
main effect of diet (CA1 [F(1,23) =14.39 p=0.0009], CA2/3 [F(1,23) =12.14 p=0.0020], DG
[F(1,23) =12.16 p=0.0020]), time (DG [F(1,23) =10.88 p=0.0031]), and a significant
interaction between diet and time in the CA1 [F(1,23) =4.37 p=0.0477], and DG [F(1,23)
=13.32 p=0.0013]. Planned post-hoc t-tests indicated a significant increase after ethanol
exposure in all regions of the hippocampus at T7: CA1 [t(10) =3.22, p=0.0092], CA2/3 [t(10)
=2.28, p=0.0457], and DG [t(10) =5.038, p=0.0005] However, by T28, the number of
hippocampal microglia returns to control levels in all regions except the CA2/3 [t(13)
=2.66, p=0.0195]. In the entorhinal cortex, microglial cell number was estimated by an
automated cell count, where no change was seen in the number of microglia between
ethanol (586.5±55.4 microglia/section, n=7) and control animals (623.3±26.7
microglia/section, n=7) at T7, therefore no further time point was examined.

60

Figure 2.4 Increase in microglia number following 4-day binge exposure

Figure 2.4. Stereological estimates indicate an increase in the number of microglia in
ethanol treated animals (n = 7; grey bars) compared with control (n = 8; black bars) at T7
in the (A) CA1 (B) CA2/CA3, and (C) DG. This increase persists twenty-eight days later
in the (B) CA2/3 in ethanols (n = 7) compared with controls (n = 7). There was no
difference in cell counts determined by image analysis between ethanols and controls at
T7 in the (D) entorhinal cortex. *p < 0.05.
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Cytokine expression also suggests low grade activation phenotype
In order to assess the functional state of microglia, cytokine levels were assayed
via ELISA. Increases in the proinflammatory cytokines IL-6 and TNF-α , are associated
with classically activated microglia, but not partially activated microglia, and can be used
to differentiate the two phenotypes of microglia (Table 2.1). IL-6 is a proinflammatory
cytokine secreted by activated microglia in response to brain injury but can also act in an
autocrine function to stimulate surrounding microglia into a phagocytic state (Chiang et
al. 1994; Woodroofe et al. 1991). Two-way ANOVA’s showed a main effect of time in
the hippocampus [F(4,59) =8.18, p<0.0001], but Bonferroni corrected post-hoc t-tests
showed no statistical difference between ethanol and control animals in the region.
However in the entorhinal cortex, two-way ANOVA indicated a significant main effect of
diet [F(1,54) =7.13 p=0.01], time [F(4,54) =2.88 p=0.03], and a significant interaction
between diet and time point [F(4,54) =4.72 p=.002] (Figure 2.5). Bonferroni corrected
post-hoc t-tests show a significant 36% decrease [t(11) =3.97, p=0.011] in IL-6 in ethanol
animals compared to controls in the entorhinal cortex at T2. Taken together, these
results indicate that inhibition of basal IL-6 expression occurs after ethanol withdrawal in
a temporally and regionally specific manner. In addition to IL-6, TNF-α is a
proinflammatory cytokine expressed by fully activated microglia and increased after
many forms of injury (Vitarbo et al., 2004). Two-way ANOVA of the hippocampus
showed a main effect of time [F(4,63) =20.77, p<0.0001], but there was no statistical
differences between ethanol and control animals after Bonferroni corrected post-hoc ttests. Despite significant main effects of both diet [F(1,54) =4.77 p=0.03], time [F(4,59)
=8.86 p<.0001] in the entorhinal cortex, Bonferroni corrected post-hoc t-tests indicated
no difference between ethanol and control animal at any time point. This lack of TNF-α
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upregulation in brain is consistent with previous reports in rats (Ehrlich et al., 2012;
McClain et al., 2011; Zahr et al., 2010), but not mice (Qin et al., 2008).
Figure 2.5 No Increased proinflammatory cytokine expression in the 4-day binge.

Figure 2.5. Concentrations of (A, B) IL-6, (C, D) TNF-α were determined by ELISA in
both the hippocampus (A, C) and entorhinal cortex (B, D). A 36% decrease of IL-6 was
measured in the (B) entorhinal cortex at T2 in ethanol animals (n = 7; black bars)
[175 pg/mg ± 8.9] compared to controls (n = 7; grey bars) [272 pg/mg ± 21.2]; however,
no change in TNF-α was seen in either the (E) hippocampus or the (F) entorhinal
cortex. *p < 0.05.
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Basal expressions of TNF-α and IL-6 were not increased following four-day ethanol
exposure, suggesting the lack of a proinflammatory response. Therefore, we examined
the effects of ethanol on the growth factor, TGF-β, as well as IL-10, an anti-inflammatory
cytokine (Fiorentino et al. 1991; Polazzi et al. 2009). A significant interaction between
diet and time point was shown in the hippocampus using a two-way ANOVA of TGF-β
[F(4,53) =4.20 p=0.005]. Bonferroni corrected post-hoc t-tests revealed a significant 26%
increase [t(11) =2.673, p=0.0434] in TGF-β in ethanol animals compared to controls at T7
(Figure 2.6). Despite a significant main effect of time point in the entorhinal cortex [F(4,47)
=18.65 p<0.0001], no difference in TGF-β was observed between ethanol and control
treated animals. In the hippocampus, a two-way ANOVA of IL-10 concentrations
indicated a main effect of time point [F(4,59) =6.71 p=0.0002], plus a significant interaction
between treatment and time point [F(4,64) =3.24, p=0.01]. Bonferroni corrected post-hoc
t-tests revealed a significant 26% increase [t(11) =3.97, p=0.011] in IL-10 in ethanol
animals compared to controls in the hippocampus at T7 (Figure 2.6). A two-way ANOVA
showed no statistically significant main effects or interaction between diet and time point
in the entorhinal cortex indicating no significant difference in the mean protein
concentration between ethanol treated animals and controls (Figure 2.6).
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Figure 2.6 Increased TGF-β and IL-10 expression after 7 days of abstinence.

Figure 2.6 Concentrations of (A, B) TGF-β (C, D) IL-10 were determined by ELISA in
both the hippocampus (A, C) and entorhinal cortex (B, D). An increase in both (A) TGF-β
(38%) (C) IL-10 (26%) was seen in ethanol animals (n = 6,7 respectively; grey bars)
compared with controls (n = 7; black bars) in the hippocampus at T7. *p < 0.05.
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BBB remains intact following four-day binge ethanol exposure
In order to assess, whether the BBB is possibly breached by four-day binge ethanol
exposure, we examined the penetration of IgG molecules during intoxication and at T2.
Penetration of IgG into the parenchyma was observed in the ventral hypothalamus
around the 3rd ventricle, a region known to lack an intact BBB under physiological
conditions (Schmidt and Grady 1993). However, qualitative analysis of IgG
immunoreactivity between Bregma -2.30mm and -4.50mm (Paxinos and Watson, 2009)
showed that both ethanol and control animals had few, if any IgG positive cells or
diffusion in the parenchyma of either the hippocampus or entorhinal cortex at T0 or T2
(Figure 2.7). Therefore, the BBB does not appear to be breached in this model.
Figure 2.7 No disruption in the BBB.

Figure 2.7 There is no disruption in the BBB following ethanol as there is little to no IgG
staining in either the (B, C, F, G) ethanol (T0: n = 8; T2: n = 6) or (A,E) control (T0 n = 6;
T2 n = 7) compared with a (D,H) kainate positive control. Scale bar = 400 μm.
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DISCUSSION
Microglia take on a variety of phenotypes, which can be used to predict the cell’s role
in brain insult or neurodegenerative disease. The major finding of this work is that both
morphological and functional evidence from these experiments support the conclusion
that binge ethanol exposure does not classically activate microglia and is consistent with
definitions of partial activation. The lack of classically activated microglia therefore does
not meet the criteria for classical definitions of inflammation. Of Raivich’s five levels of
microglial activation (Raivich et al., 1999a), these data support that four-day binge
ethanol exposure only appears to activate cells up to stage 2. A step-wise progression
is noted beginning while the animals are intoxicated (T0) where stage 1 (Table 2.1) or
low level “alert” activation begins to occur and persists for at least twenty eight days
according to [3H]-PK-11195 autoradiography for the TSPO receptor and OX-42 (CR3)
immunoreactivity. Both markers are upregulated during and after four-day binge alcohol
exposure. In addition, the morphology of OX-42 positive cells in ethanol-exposed brains
supports that microglia are “alert” and “homing” as they appear less ramified with thicker,
bushier processes (Figure 2.2). A stage 2 level of activation, or “proliferation and
homing,” was suggested previously with the observation of proliferating microglia (Nixon
et al., 2008). That microglia proliferate and home to sites of damage is further supported
by the increased numbers of Iba-1+ microglia observed at T7 in all regions of the
hippocampus, which persists in the CA2/3 at T28 (Figure 2.4). Importantly, the highest
indices of activation, proliferation and increased number, are observed well after the
peak of alcohol-induced cell death during intoxication (Crews 2000; Kelso et al. 2011),
which suggests that alcohol-induced microglial activation is a consequence of alcoholinduced cell death.
However, neither TSPO nor CR3 upregulation indicates the level of activation.
Therefore, in order to determine microglia phenotype, more classical markers of full
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activation were evaluated. Neither OX-6 nor ED-1 were detected in the brain
parenchyma, which indicates that few, if any, microglia have been activated to either a
phagocytic or bystander activation state (Kato et al. 1995). Indeed, with the addition of
these data, ED-1 has been exhaustively examined following four-day binge ethanol
exposure, the most acutely damaging model of an AUD, and at no time point examined
have ED-1-positive cells ever been found inside the brain parenchyma (McClain et al.,
2011; Nixon et al., 2008). Therefore, morphology, number and marker data converge to
support that microglia are only partially activated, specically to at least stage 2 in the
hippocampus and to stage 1 in the entorhinal cortex.
Activated microglia not only change morphologically but also functionally as they
secrete cytokines and growth factors that may impact the surrounding environment.
Similarly, these cytokines can have either damaging or protective/reparative effects
depending on the phenotype or level of microglial activation (Raivich et al. 1999a;
Suzumura et al. 2006). Therefore, we examined key cytokines at critical time points of
previously reported cellular events following four-day binge exposure. Cytokine
expression following binge ethanol exposure also indicated that microglia are only
partially activated. Proinflammatory TNF-α was not changed at any time point, IL-6 was
selectively decreased at T2 in entorhinal cortex, the time of microglial proliferation,
whereas anti-inflammatory cytokines, IL-10 and TGF-β, which can be secreted by
alert/homing microglia, were selectively increased at T7 in the hippocampus. Partially
activated microglia secrete both TGF-β and IL-10, and are known to suppress microglia
activation and subsequent neuronal damage (Ledeboer et al. 2000; Sharma et al. 2011;
Spittau et al. 2012). The increase IL-10 and TGF-β seven days after ethanol exposure
(T7) in the hippocampus comes after significant neuronal damage in this region and,
intriguingly, coincides with reactive neurogenesis (Kelso et al., 2011 Nixon and Crews,
68

2004; Obernier et al., 2002a). However, TNF-α and IL-6, released in the highest levels
of activation, were not increased at any time point in either the hippocampus or
entorhinal cortex (Bethea et al. 1999; Stoll et al. 2000). The lack of effect on TNF-α is
consistent with recent reports from multiple laboratories that TNF-α is not increased in
rats following excessive alcohol exposure (Ehrlich et al., 2012; McClain et al., 2011; Zahr
et al., 2010), though conflicts with reports in mice (Alfonso-Loeches et al. 2010; Qin and
Crews 2012a; Qin et al. 2008). It is important to note that the source of these cytokines
was not determined in the present study or the cited reports as reactive astrocytes also
secrete many of the same cytokines (Lau and Yu 2001). Astrocytes are activated in the
four-day binge model used and other alcohol models, though in a more delayed time
course than that observed for microglia (Kelso et al., 2011). Because of the overlap in
microglia and astroglia activation at T7 in this model, it is impossible to definitively link
microglia activation with the secretion of particular cytokines. An important future
discovery will be to show the cellular source of these cytokines in vivo. In summary,
cytokine expression patterns following four-day binge alcohol exposure are consistent
with that observed in immunohistochemical and morphological analyses – microglia
phenotype is not one of classical activation, but merely partial activation.
The activation state of microglia is critical to understanding their role in alcoholic
neuropathology. Microglia progress stepwise through these various phenotypes, each of
which is predictive of the cell’s role in homeostasis/neuroprotection versus
neurodegeneration (Raivich et al. 1999a; Schwartz et al. 2006; Vilhardt 2005). Although
the concept of a graded state of activation (phenotype) has resolved the debate as to
whether microglia are “good” or “bad,” each insult still results in a distinct response
(Harting et al., 2008; Lai and Todd, 2008; Saijo and Glass, 2012). Even various patterns
of alcohol intake produce a distinct response. As shown here, four-day binge ethanol
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exposure, which is an acutely damaging event compared to more chronic models, only
produces partially activated microglia. Partially activated or low level phenotypes are
more closely associated with roles in homeostasis and neuroprotection and therefore
alcohol-activated microglia may be playing a role in neuroprotection, repair, or in the
hippocampal DG, regeneration (Battista et al. 2006; Engelsberg et al. 2004). Although it
may seem surprising that a brain insult as severe as high blood alcohol concentrations
and alcohol-induced neurodegeneration, does not result in an overt, phagocytic level of
reactive microgliosis, not all types of brain injury result in a full phagocytic, i.e. classical,
microglial response (Graeber et al. 1998). Indeed, a recent report details phagocytosis
independent of fully activated microglia (Sierra et al. 2010) and multiple reports show
that partially activated microglia are necessary in neuroprotection and axonal
regeneration (Shokouhi et al. 2010; Wainwright et al. 2009).
Intriguingly, intermittent exposure to ethanol results in evidence of more classically
activated microglia such as TLR4 upregulation (Alfonso-Loeches et al. 2010; FernandezLizarbe et al. 2009). Greater levels of activation with intermittent exposure models leads
us to speculate that the initial exposure may serve as a priming stimulus to microglia
such that subsequent exposures result in over-response as seen in other
neurodegenerative disease models (Bilbo and Schwarz 2009; Perry et al. 2003). The
concept of microglia priming would explain why more classic-like activation is observed
with multiple exposures or multiple intoxication/withdrawal cycles as that used by Qin
(Qin et al., 2008), as opposed to our single cycle of prolonged intoxication then
withdrawal and why the pattern of drinking is more associated with gliosis than the level
of consumption (Riikonen et al. 2002). Unfortunately, these and other data support that
microglia remain “primed” or partially activated for long periods of time after exposure.
For example, [3H]-PK-11195 remains upregulated months after alcohol exposure
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(Obernier et al. 2002b; Syapin and Alkana 1988) and the number of microglia remains
increased at least a month after the binge in some regions (Figure 2.4). The long-term
persistence of some level of activation supports the theory that cells could be “primed”
by the initial damaging binge exposure. Furthermore, repeated cycling could also
change the microglia response to secondary neuroimmunomodulators such as systemic
inflammation (Qin et al., 2008; Zahr et al., 2010) which could be crucial when
considering the large number alcoholics have systemic inflammation associated with
liver disease (Polednak 2012; Seth et al. 2011; Wang et al. 2012b). This observation is
important clinically as human binges tend to occur in an episodic nature and bingepattern drinkers have a greater likelihood of neurodegeneration (Hunt, 1993). Thus, our
data is consistent with the idea that an initial “hit” of binge-induced damage appears to
partially activate microglia as a consequence of damage, but if this partial activation
primes microglia, secondary “hits” or binge exposure could “polarize” or result in a more
classical activation phenotype and/or inflammation. Although this study did not address
polarization of microglia, nor the specific definitions associated with alternative or M2
activation, this could be a logical next step of the current work. A defining hallmark of
classical inflammation is a compromised BBB, which, based on an examination of IgG
expression, is not evident in the four-day binge model, the most severe of AUD models.
Indeed, these data agree with evidence from less acutely damaging but longer term,
chronic models of exposure such as 12-month 20% ethanol in the drinking water (Ehrlich
et al., 2012). Other alcohol models, that have enhanced proinflammatory cytokine
expression, do show BBB disruption, further supporting the theory that BBB disruption is
necessary for a true neuroinflammatory event (Abdul Muneer et al. 2012). Importantly,
the lack of evidence for a BBB compromise in this model strongly supports that classical
inflammation does not occur with four-day binge exposure. Although this is only one
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model of an AUD, the well-defined cell death and degeneration profile coupled with data
reported here does not indicate that classical inflammation drives alcohol-induced brain
damage or that inflammation, according to classical definitions, occurs at all in this
model.
The timecourse of expression of these various microglial markers and cytokine
effects coupled with published timecourses of alcohol-induced cell death in this model
(Crews et al., 2000; Kelso et al., 2011) support that alcohol-induced microglia activation
is a consequence, not a cause of alcohol neurotoxicity. Alcohol-induced partial
activation suggests a beneficial role of microglia in this model of an AUD, especially as
no reports to date have observed fully activated, phagocytic microglia in brains from
alcoholics. Indeed, if you remove microglia in many forms of neurodegeneration,
worsened outcomes occur (Wainwright et al., 2009). Microglia have diverse roles in
homeostasis, including newly defined roles in synaptic plasticity and neurotransmission
(Tremblay and Majewska 2011) and it is not known, nor revealed by these data, how
partial activation might affect their homeostatic actions in synaptic plasticity. Intriguingly,
the lack of phagocytic microglia could have implications for synaptic pruning and
remodeling, especially in ongoing neurogenesis in the DG (Tremblay and Majewska,
2011). Thus, the inflammation hypothesis of AUD and targeting microglia in the
treatment of AUDs must be considered with caution. Neuroinflammatory responses
alone do not lead to AUDs and many of the reported microglial activation markers are
expressed in the beneficial partially activated or acquired deactivated microglia that help
to resolve and repair damage (Colton and Wilcock, 2010). Thus, it is not just that these
microglia are activated by excessive alcohol exposure; the critical information is their
phenotype. Therefore, these data do not rule out a role for microglia in AUDs, but do not
support a direct relationship between alcohol, microglial activation and inflammation
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driven neurotoxicity. Careful consideration of these various current and previous
studies, however, suggest that this partial activation phenotype could be consistent with
a “primed” state such that repeated bouts of damaging, excessive alcohol intake, which
is consistent with binge-benders in AUDs, may eventually result in highly or classically
activated microglia and a proinflammatory state. The immediacy of microglial activation
during alcohol intoxication, which was observed here, suggests that controlling the
activation state of microglia during ethanol exposure may be a potential therapeutic
target for AUDs. If microglia can be limited to only partial activation, perhaps they may
be beneficial to endogenous repair systems after alcohol-induced neurodegeneration.

Copyright © S. Alex Marshall
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Chapter 3: Early evidence of microglial activation in an alcohol-induced
neurodegeneration model
INTRODUCTION
Excessive consumption of ethanol, one of the key characteristics of an AUD, can
result in neurodegeneration in the corticolimbic pathway of human alcoholics and has
been associated with a variety of cognitive deficits (Beresford et al. 2006; Parada et al.
2011; Pfefferbaum et al. 1992; Sullivan et al. 1995). In fact, alcohol-induced cognitive
impairments are the second leading cause of dementia, behind only Alzheimer’s
Disease (Eckardt and Martin 1986). One mechanism that has been proposed to cause
alcohol-induced neurodegeneration is neuroinflammation (Crews 2012). This
mechanism has been inferred from the brains of post-mortem alcoholics that have
increased microglial activation (He and Crews 2008) as well as modulations of
transcriptions factors associated with innate immune gene induction like NF-kB (Okvist
et al. 2007). However, recent studies using the Majchrowicz model of an AUD, which
consistently shows alcohol-induced neurodegeneration (Collins et al. 1996; Kelso et al.
2011; Obernier et al. 2002b), have proposed that microglial activation following this
exposure is not inflammatory but alternatively has a beneficial phenotype that may be
involved in homeostatic mechanisms (Marshall et al. 2013; McClain et al. 2011; Zahr et
al. 2010a). Furthermore, studies using the Majchrowicz AUD model suggest that
microglial activation is in response to neuronal damage and not the cause (Marshall et
al. 2013; McClain et al. 2011). These studies focused on alcohol microglial effects in
snapshots during recovery following the four-day binge model; however, it has been
shown that alcohol-induced brain damage occurs earlier during the binge exposure
(Hayes et al. 2013; Obernier et al. 2002a). Because microglia respond quickly to
environmental perturbation (Nimmerjahn et al. 2005), it is perceivable that microglial
activation would occur concurrently with neurodegeneration and well before the end of
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the four-day binge paradigm. Furthermore if microglia activation is a driving force of
neurodegeneration in this model, microglia activation would occur before evidence of cell
death seen after just two days of exposure (Hayes et al. 2013; Obernier et al. 2002a).
This study examines how early this activation occurs within the Majchrowicz AUD model.
Determining the immediacy of microglial activation is an important factor in
understanding their role within AUDs and alcohol-induced neurodegeneration. Early,
immediate activation and neuroinflammation are necessary defense mechanisms in
response to damage. Acute microglial activation has been described as vital for
“housekeeping” (Nimmerjahn et al. 2005) and “nursing” (Streit 2002b) in the CNS. If
microglia are not responding after immediate signs of damage, it could indicate that
microglial function is compromised. Furthermore, modulation of neuroinflammatory
pathways has been proposed as a potential therapeutic for alcohol-induced brain
damage (Crews 2008), and other neurodegenerative disorders have shown determining
the timing of immune modulation is crucial for therapeutic outcomes (Ceulemans et al.
2010; Kriz 2006).
The current studies examine the immediacy of the microglial response using [ 3H]PK11195 binding, a sensitive marker of microglial activation. [3H]-PK11195 binding was
measured following various durations of ethanol exposure. Stereological estimates of
microglia cell numbers were used to help interpret [3H]-PK11195 binding results as
densitometric analysis can be convoluted by changes in cell number.
MATERIALS AND METHODS
Experimental Model of an AUD
All included procedures were approved by the University of Kentucky Institutional
Animal Care and Use Committee as well as Guidelines for the Care and Use of
Laboratory Animals (NRC, 1996). Male Sprague-Dawley rats (n=51; Charles River
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Laboratories, Raleigh, NC) arrived at 275-300g and were allowed five days for
acclimation to single housing conditions in a University of Kentucky AALAC accredited
vivarium with a 12h light:dark cycle. During the acclimation period, animals were handled
for three days and had ad libitum access to food and water.
Rats were divided into three groups and subjected to a modified version of the
Majchrowicz model of an AUD for either 1, 2, or 4 days (Hayes et al. 2013; Majchrowicz
1975; Morris et al. 2010b). This model has previously been described in chapter two,
and the binge methods used in these experiments were identical outside of the number
of days of exposure. Rats were euthanized within hours of the last dose of ethanol or
control diet. BECs were determined from blood taken following the last dose of ethanol
for animals exposed to one or two days of ethanol but following the seventh dose of
alcohol for animals with four days of exposure as described in chapter two. Samples
were centrifuged to obtain serum and stored at -20˚C. BECs were determined from
triplicate runs of serum using an AM1 Alcohol Analyser with a 300mg/dL external
standard for calibration (Analox, London, UK). The average BECs were reported as
mg/dL.
Autoradiography
Changes in the expression of the mitochondrial translocator protein 18kDa
(TSPO) were measured using densitometric analysis of [3H]-PK11195 binding. This
radioligand was used to assess microglial activation following one or two days of ethanol
because of its high sensitivity in determining activation (Benavides et al., 2001;
Readnower et al., 2010). Autoradiography was conducted as described in previously
(Kelso et al. 2006; Sparks and Pauly 1999) and are identical to chapter two that showed
upregulation of TSPO after four days of exposure in this model (Marshall et al. 2013).
However, the control animals in these studies were not collapsed for analysis. The
76

relative binding was determined using ImageJ software and expressed as percent
control.
Immunohistochemistry
Immunohistochemical techniques were similar to that previously reported
(Marshall et al. 2013; McClain et al. 2011). Rat euthanization, brain extraction, and
tissue treatments were identical to that stated in chapter two. Every twelfth section was
used in an immunohistochemical staining process using an antibody against Wako,
Richmond, VA). This Iba-1 antibody recognizes a calcium binding protein that is
specifically found in microglia (Heizmann and Hunziker, 1991; Imai et al., 1996; Ito et al.,
1998). Iba-1 is present in microglia regardless of phenotype but is upregulated upon
activation (Donato, 1999; Donato, 2003; Hwang et al., 2006). Immunohistochemical
procedures were identical to that previously described in chapter two. Tissue was
mounted onto slides and coverslipped using Cytoseal® (Stephens Scientific, Wayne,
NJ).
Quantification of Iba-1 Cells
Slides were coded so that experimenters were blinded to the treatment group
during quantification. Unbiased stereological methods were used to estimate the number
of Iba-1+ cells in the subregions of the hippocampus using the newCAST Stereology
System (Visiopharm, Hoersholm, Denmark) installed on a Dell Precision 380 workstation
coupled to an Olympus BX-51 microscope (Olympus, Center Valley, PA). The
stereological methods used were identical to our previous report (Marshall et al. 2013)
as described in chapter two. For all stereological quantifications, coefficient of error
ranged from 0.010 to 0.037 and averaged 0.023 ± 0.001 (Gundersen et al., 1999).
Image Pro Plus, an image analysis system that has been shown to be a valid
alternative method for determining cell number (Francisco et al. 2004), was used to
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quantify Iba-1+ cells in the entorhinal cortex (Marshall et al. 2013). The methods used
were identical to that reported in chapter two. The number of cells in each section was
averaged and expressed as Iba-1+ cells/section .
During stereological estimates, the appearance of dystrophic microglia was noted
in the molecular layer of the DG. Dystrophic microglia have a distinct morphology
compared with other microglial phenotypes. Dystrophic microglia have cytorrhexis or
cytoplasmic fragmentation as well as beaded processes (Streit et al. 2009). Therefore,
the number of dystrophic microglia was determined within the molecular layer of the DG
where this phenomenon was initially observed. Microglia were characterized as being
dystrophic if they possessed fragmented cell bodies and had the appearance of beaded
processes (Streit et al. 2004b). Dorsal hippocampal sections stained with Iba-1 between
Bregma -2.30mm and -4.50mm were examined for the dystrophic characteristics. Profile
counting methodology was performed using a 60x oil immersion lens due to the
infrequency and inhomogeneous distribution of these cells (Morris et al. 2010a; Popken
and Farel 1997). Counts are expressed as cells/section.
Enzyme Linked Immunosorbent Assay
Because our previous studies indicate that microglia are not classically activated
in this model, only brain derived neurotrophic factor (BDNF) was assessed after four
days of ethanol exposure. Although not exclusively secreted by microglia, enhanced
BDNF expression by microglia can afford neuroprotection while decreases are
associated with neuronal loss (Liao et al. 2012). The hippocampus was selected as
BDNF has been previously shown to be more susceptible to alcohol-induced effects on
neurotrophic factors than the entorhinal (Miller 2004; Miller and Mooney 2004).
Furthermore, BDNF is highly concentrated in the hippocampus compared with other
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brain regions (Phillips et al. 1990). Tissue processing for ELISA assays was identical to
chapter two.
BDNF content was determined using a Millipore ELISA kit (Billerica, MA; product
#CYT306) in accordance with the instructions provided. The total protein concentration
was determined using a Pierce BCA Protein Assay Kit (Thermo Scientific, Rockford, IL).
Samples were run in duplicate for both the ELISA and BCA and absorbance was
measured at 450nm or 595nm, respectively, using a DXT880 Multimode Detector plate
reader (Beckman Coulter, Brea, CA). Concentrations were calculated using the line of
best fit from corresponding standards and are expressed as pg of cytokine/mg of protein.
Statistical Analysis
Prism Version 5.04 (GraphPad Software, Inc. La Jolla, Ca) was used for all
statistical analyses. Behavioral intoxication scores were analyzed with a Kruskal Wallis
test followed with Dunn’s multiple comparison test, but BECs and ethanol dose per day
were analyzed using a one-way ANOVA followed by Tukey’s post-hoc test if significance
was determined by one-way ANOVA. Two-way ANOVAs were used for analysis of [3H]PK11195 binding, Iba-1+ cell number, and dystrophic microglia number. Post-hoc
Bonferroni corrected t-tests were used following two-way ANOVAs if a main effect or
significant interaction was found. Planned post-hoc t-tests were chosen as the
comparison of interest was mainly the effect of ethanol diet on measured parameters.
Entorhinal cortex and each region of the hippocampus were analyzed separately for [3H]PK11195 binding and Iba-1+ cell number. BDNF concentrations were compared using a
two-tailed, unpaired t-test. All data sets were expressed as mean ± standard error of the
mean and analyses considered significantly different if p<0.05
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RESULTS
Animal model data
BECs were similar among all groups despite variations in binge ethanol exposure
duration as shown in Table 3.1. The average BEC for all animals was 344.5 ± 10.2
mg/dL and is comparable to what has been shown previously with this model (Marshall
et al. 2013; Morris et al. 2010b). However, the Kruskal Wallis, revealed significant a
difference in intoxication behavior variance [H(4) =16.67, p=0.0022]. Dunn’s post-hoc
analysis of behavioral score revealed a significantly lower behavioral score for animals
exposed to ethanol for one day versus four. Accordingly, As dose is dependent upon
the intoxication behavioral score, the average administered daily ethanol dose was also
significantly different as shown using a one-way ANOVA [F(4,28) =13.21, p<0.0001].
Bonferroni post-hoc analysis of the average dose per day revealed that animals with
only one day of exposure received significantly more ethanol per day than either the two
or four-day exposed rats. Differences in average daily dose and intoxication behavior
were expected as variations in the duration of ethanol exposure have been previously
shown to affect these parameters (Hayes et al. 2013).
Table 3.1 Experiment Two Animal Model Data
Days of
Intoxication
Dose
BEC
Experiment
Binge
behavior
(g/kg/day)
(mg/dl)
Exposure
(0–5 scale)
One (n=5)
0.5± 0.1*
13.4 ± 0.4*
304.1 ± 19.0
Autoradiography
Two (n=5)
1.6 ± 0.1
10.3 ± 0.3
384.8 ± 25.9
Two (n=8)
1.7 ± 0.2
9.9 ± 0.5
300 ± 18.6
Immunohistochemistry
Four (n=7)
2.2 ± 0.2
9.0 ± 1.2
364.8 ± 23.0
ELISA
Four (n=7)
1.8 ± 0.1
9.6 ± 0.4
371.3 ± 10.4
Table 3.1 No statistical difference in BEC’s were observed despite differences in the
intoxication behavior and dose per day in animals that only received one day of ethanol
exposure. *p<0.05
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Two days of EtOH exposure results in microglial activation
Binding of [3H]-PK11195 after autoradiography was only measured after one and
two days of ethanol exposure as it has been previously shown that [3H]-PK11195 is
increased after four days of ethanol exposure (Marshall et al. 2013). No difference was
apparent after either one or two days of exposure in binding of the radioligand [3H]PK11195 in the CA1, DG, or entorhinal cortex compared with controls (Figure 3.1);
however, a main effect of diet was observed in the binding of [3H]-PK11195 in the CA2/3
region of the hippocampus [F(1,16) =9.43, p=0.0069]. No significant differences were seen
in CA2/3 after one day of exposure, but post-hoc t-tests indicated a significant binding
increase of approximate 20% after two days of ethanol exposure [t(8) =4.88, p=0.0018].
Ethanol decreases the number of microglia
The total number of microglia was decreased across multiple regions of the
hippocampus of ethanol treated animals compared with controls after both two and four
days of ethanol exposure (Figure 3.2). Two-way ANOVAs indicated a significant main
effect of diet in the CA1 [F(1,26) =24.49 p<0.0001], CA2/3 [F(1,26) =16.38 p=0.0004], DG
[F(1,23) =43.03 p<0.0001], entorhinal cortex [F(1,26) =4.64 p=0.0406], and a significant
interaction between diet and time in the CA2/3 [F(1,26) =5.98 p=0.0216]. Planned post-hoc
t-tests indicated a significant decrease in microglia number after ethanol exposure in all
regions of the hippocampus and the entorhinal cortex after four days of ethanol
exposure: CA1 [t(12) =3.18, p=0.0158], CA2/3 [t(12) =3.41, p=0.0104], DG [t(12) =4.70,
p=0.0010], and entorhinal cortex [t(12) =2.83, p=0.0302]. However, only microglia number
within the CA1 [t(14) =4.79, p=0.0006] and DG [t(14) =4.53, p=0.0010] were decreased
following two days of ethanol exposure (Figure 3.2).
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Figure 3.1 Increased [3H]-PK-11195 following EtOH Exposure

Figure 3.1. Representative false color autoradiographs depicting [3H]-PK-11195 binding
are shown for (A) controls (n = 5; black bars) as well as ethanol (grey bars) after (B) one
day of exposure (n=5) or (C) two (n = 6). The legend in the top right corner shows how
the false color reflects the intensity of binding. Quantitative analysis of the extent of
binding are graphed for the (D) CA1, (E) CA2/3, (F) DG, and (G) entorhinal cortex. An
increase in binding was seen after two days of exposure in both the CA2/3 region as well
as the DG. *p < 0.05.
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Figure 3.2 Decrease in microglia number during intoxication

Figure 3.2. Stereological estimates indicate a decrease in the number of microglia in
ethanol treated animals (n = 7; grey bars) compared with control (n = 7; black bars) after
four days of exposure in the (A) CA1 (B) CA2/CA3, and (C) DG. Automated cell counts
within also indicated a decrease in microglia number in the (D) entorhinal cortex. This
decrease can be seen after two days of exposure in the (A) CA1 and (C) DG in ethanols
(n = 8) compared with controls (n = 8). *p<0.05.

Microglia with the unexpected dystrophic morphology were observed in the DG
molecular. These oddly shaped cells were quantified using profile counts. Dystrophic
microglia, which have been shown to be associated with microglial cell death, were
increased following both two and four days of ethanol exposure in the molecular layer of
the DG (Figure 3.3). Two-way ANOVAs indicated a significant main effect of diet F(1,25)
=16.46 p=0.0004] and time F(1,25) =8.91 p=0.0063]. Importantly, planned post-hoc t-tests
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indicated a significant increase in dystrophic microglia after ethanol exposure after two
[t(13) =3.37, p=0.0102] and four [t(12) =2.67, p=0.0406] days of exposure.

Figure 3.3 Increase in dystrophic microglia during intoxication

*

*

Figure 3.3. Dystrophic microglia in (A,C) ethanol treated animals are indicated by arrows
in representative images. Panel A depict the atypical morphology associated with
dystrophic microglia. The arrow points directly at the fragmented cell body with the
beaded process. Panel C shows the juxtaposition of a dystrophic microglia to a resting,
quiescent cell with typical morphology. Profile counts indicate an increase in the number
of (B) dystrophic microglia in ethanol treated animals (n = 7) compared with controls
after two (n=8) and four days (n=7) of exposure in the molecular layer of the DG. *
p<0.05
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Neurotrophic Factor Decreased by Ethanol Exposure
The loss of microglia was accompanied by a decrease in the concentration of
BDNF after four days of ethanol exposure in the hippocampus (Figure 3.4) according to
t-test [t(10) =4.22, p=0.0018].
Figure 3.4 Decreased in BDNF following 4 Days of Ethanol Exposure

Figure 3.4 Concentrations of BDNF were determined by ELISA in the hippocampus.
There was a 31% decrease in BDNF in ethanol treated animals (n = 7; grey bar)
compared with controls (n = 5; black bars). *p < 0.05.

DISCUSSION
Neuroinflammation has been suggested as source of alcohol-induced damage,
but the model of alcohol-induced neurodegeneration used in this report induces lowgrade, anti-inflammatory microglial activation that is subsequent to neurodegeneration
(Marshall et al. 2013; McClain et al. 2011). This report shows that activation occurs after
just two days of ethanol exposure as evidenced by the upregulation of the sensitive
microglial activation marker, [3H]-PK11195. Although this change is slight (20%)
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compared to four days (250%) of exposure (Marshall et al. 2013), it is still significant.
This one and two day exposure model has recently been shown to cause
neurodegeneration in both the hippocampus and the entorhinal cortex (Hayes et al.
2013). Whereas neurodegeneration begins after just a single day exposure of ethanol
(Hayes et al. 2013), we have shown here that the microglial response is detectable after
two days of exposure. The small increase in activation as well as the chronological
order of activation and neuronal damage suggests that microglia activation is a response
to the initial neurodegeneration induced by alcohol exposure as has been previously
proposed (Marshall et al. 2013). Because four days of ethanol exposure does not elicit
classical signs of activation like phagocytosis or expression of MHC-II (Marshall et al.
2013), it can be inferred that upregulation of [3H]-PK11195 after two days causes
microglia to be partially or alternative activation as well, albeit not specifically
characterized in this report. This study is the first in vivo study to show that such an
acute exposure causes microglial activation, but the evidence concurs with in vitro
studies showing activation with acute exposure (Bell-Temin et al. 2013).
One criticism of densitometric analysis is the inability to determine if measured
differences are due to an increase in numbers of cell expressing the ligand or a change
in the protein expression profile. Therefore, the number of microglia was quantified by
stereology (hippocampus) or automated cell counts (entorhinal cortex). Both two and
four days of binge ethanol exposure caused a decrease in the number of Iba-1+ cells.
This finding concurs with human studies that showed a reduction in the number of
microglia in the hippocampus of human alcoholics (Korbo 1999) but not with others that
showed increases in other brain regions (He and Crews 2008). The decrease in the
number of microglia observed indicates that the increases in [3H]-PK11195 reported after
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two days of ethanol exposure here and after four days of exposure in chapter two are
due to increased activation of microglia.
The reduction in microglia found in regions with alcohol-induced
neurodegeneration is surprising because the normal function of microglia is to migrate to
areas of damage (Noda and Suzumura 2012). Upon activation, microglia can proliferate
and begin to secrete cytokines that attract other microglia. A reduction in microglial seen
in both the hippocampus and entorhinal cortex may be indicative of dysfunction as
microglial migration to areas of damage is a key component of their function (Damani et
al. 2010; Tremblay et al. 2013), but the methods used herein cannot directly contribute
the reduction in number to a problem with motility as microglia may directly cause glial
damage (Korbo 1999). However, a loss of microglia has been shown to exacerbate
damage and represents an alternative mechanism by which alcohol-induced microglia
activity may contribute to neurodegeneration (Streit et al. 2009; Wainwright et al. 2009).
The idea that microglial dysfunction can contribute to neurodegeneration is a
fairly recent concept (Streit et al. 2009; Streit and Xue 2009). While chronic, overactivation of microglia has repeatedly been proposed as a mechanism for
neurodegeneration in various disease states (Lull and Block 2010). The vast effects of
microglia mean that the loss of the homeostatic and recovery functions afforded by
microglia can also lead to neurodegeneration (Streit et al. 2009). The pathways that
lead to neurodegeneration caused by a loss of homeostatic mechanisms afforded by
microglia has not been as widely studied as the chronic over-activation pathways, but in
models of Alzheimer’s Disease and aging has been characterized by either microglial
motility impairment (Damani et al. 2010) or the appearance of dystrophic or senescent
microglia (Streit et al. 2004b).
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Concurrent with the loss of microglia is the increase in the appearance of
dystrophic microglia in the molecular layer of the DG. Increased dystrophic, also known
as senescent, microglia have been proposed as a mechanism of neurodegeneration and
dementia in aging studies as microglia have a distinct role in neurotrophic support both
in pathological and nonpathological conditions (Streit et al. 2009). For example, following
neuronal injury the brain may recover by increasing neurogenesis (Nixon and Morris
2008). Increased senescent microglia may disrupt this recovery mechanism as
microglia are involved at various levels within reactive neurogenesis including
proliferation (Morgan et al. 2004), differentiation (Cacci et al. 2008), and neuronal
survival through secretion of neurotrophic factors (Kohman and Rhodes 2013; Nakajima
et al. 2001; Yoneyama et al. 2011). Alternatively, microglia can act to remove cellular
debris from degenerating cells, which also aids in the recovery from brain damage (Czeh
et al. 2011; Tremblay et al. 2013). Even in quiescence without any pathological
condition, microglia act as alarm systems constantly surveying the neuronal environment
and using their ramified branch projections to probe for any abnormalities in the
parenchyma (Nimmerjahn et al. 2005). The loss of any of these microglial properties of
mechanisms makes the increase in the number of dystrophic microglia coupled with a
loss in the number of a critical concern in normal neuronal function and/or response to
damage.
Given that the microglial response seen after binge ethanol exposure appears to
be partial activation which is associated with neurotrophic support, the decreases in
BDNF seen herein may potentially be due to the dysfunction of microglia. The normal
response of microglia following neuronal injury and activation is to upregulate production
of BDNF (Miwa et al. 1997; Nakajima et al. 2001). However, because BDNF is a
secreted protein produced by astrocytes, neurons, and endothelial cells (Bejot et al.
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2011), this study cannot directly tie the decrease in BDNF solely to microglial function.
Alcohol-induced deficits in microglia number and increased senescence may be partially
responsible for decreased BDNF concentrations. Decreased BDNF during intoxication
found here agrees with previous reports on the effect of ethanol on hippocampal BDNF
in vapor inhalation models of an AUD (Tapia-Arancibia et al. 2001) as well as the
decreased levels seen in the serum of human alcoholics (Davis 2008; Joe et al. 2007).
BDNF is associated with the survival of neurons following proliferation (Lee and Son
2009; Lee et al. 2002; Loeliger et al. 2008). Intriguingly, the deficits in BDNF occur
simultaneously with the reduction of cell survival of newly proliferated cells previously
reported in this model (Nixon and Crews 2002). Together reduced newborn cell survival
and BDNF levels further alludes to a potential role of microglia dysfunction within
alcohol-induced neurodegeneration.
These results altogether show that microglia become activated early within the
Majchrowicz AUD model, but likely in response to alcohol-induced neurodegeneration
given the low-nature of activation as well as the chronological order of activation and
neuronal cell death. This early activation, however, is concurrent with signs of microglial
loss and the appearance of dystrophic microglia. The loss of the neuroprotective function
of microglia during intoxication may serve as a potential source of neurodegeneration by
inhibiting recovery. A direct relationship between the effects of alcohol on microglia and
neurodegeneration is still yet to be elucidated, but interpretations of the data included
herein provide an alternative view on how microglia may be involved with alcoholinduced neurodegeneration. It has become increasingly evident that multiple
neurobiological systems are involved with alcohol brain damage (Crews and Nixon 2009;
Kruman et al. 2012), but the loss of neuroprotection/homeostatic functions of microglia
could further cause deterioration in an already vulnerable system. Rescuing microglia
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loss during intoxication through pharmacological agents may provide a valid, novel
therapeutic option for reduction of alcohol-induced neurodegeneration.

Copyright © S. Alex Marshall
90

Chapter 4: Ethanol can potentiate the primed microglial response in an alcoholinduced neurodegeneration model
INTRODUCTION
Chronic, excessive consumption of alcohol can result in neurodegeneration
(Crews and Nixon 2009; Pfefferbaum et al. 1992; Zahr et al. 2011). This
neurodegeneration and its associated cognitive deficits are thought to play a role in the
development of an AUD (Crews and Boettiger 2009; Koob and Le Moal 1997).
Understanding how this neurodegeneration occurs may provide a therapeutic target for
the treatment of AUDs. Recently, it has been proposed that microglial activation is a
potential mechanism that causes neurodegeneration in individuals who suffer from an
AUD (Crews et al. 2011; Qin et al. 2013). Evidence in the brain of human alcoholics
suggest that excessive alcohol consumption leads to microglial activation (He and Crews
2008; He et al. 2005), but whether this activation is causative in alcohol-induced
neurodegeneration is currently debatable. This debate is due in part to variations in the
level of microglial activation among AUD models with brain damage (Qin et al. 2008;
Zahr et al. 2010a). In neurodegenerative diseases where microglial activation has been
shown to be a driving mechanism in neuronal cell loss (Block and Hong 2005; Brown
and Neher 2010; Smith et al. 2012), microglia are fully activated over a long period of
time secreting proinflammatory factors and undergoing uncontrolled phagocytosis
(Brown and Neher 2010; Fricker et al. 2012; Streit et al. 2004a). While some AUD
models indicate proinflammatory microglia (Qin and Crews 2012a; Qin et al. 2008; Ward
et al. 2009a), others report a more low-grade level of activation that may be beneficial or
neuroprotective (Marshall et al. 2013; McClain et al. 2011; Zahr et al. 2010a). Two
reasons that have been proposed for the discrepancies across models in microglial
activation are (1) intermittent versus sustained intoxication within a model as well as (2)
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the presence or lack of systemic immune influences (Marshall et al. 2013; Zahr et al.
2010a).
The Majchrowicz AUD model is a model with high BECs that likely do not fall
below intoxication (Morris et al. 2010b). This model also has an intact BBB that prevents
systemic immune influences on microglia (Marshall et al. 2013). Likewise, this model has
recently been reported as inducing low-grade microglial activation rather than
proinflammatory microglia (McClain et al. 2011). Although the Majchrowicz model
produced evidence of low-grade activation, microglial activation and increases in cell
number were shown to be persistent and lasted at least a month after the last dose of
ethanol (Marshall et al. 2013; Obernier et al. 2002b). Persisting, low-level activation can
alter the neuroimmune system such that future neuroimmunomodulators have an
exacerbated or potentiated response (Bilbo and Schwarz 2009; Bland et al. 2010). A
potentiated response can change microglial from a low-grade, neurotrophic state to the
more classical activation phenotype associated with neuronal damage (Lewis 2012;
Norden and Godbout 2013). This phenomenon is known as microglial priming and is an
alternative explanation for the discrepancy in the level of activation seen between AUD
models (Dilger and Johnson 2008; Marshall et al. 2013; McClain et al. 2011; Norden and
Godbout 2013). Alcohol exposure may prime microglia so that subsequent insulting
exposures or intermittent bingeing act as secondary neuroimmune modulators that then
alter the microglial response.
Ethanol’s ability to act as a priming agent and exacerbate the neuroimmune
response of stimuli that mimic systemic infection has already been shown (Qin and
Crews 2012a; Qin et al. 2008; Qin et al. 2013). The current study determines whether
ethanol exposure alone can act as both the priming agent and secondary neuroimmune
modulator by giving a secondary “hit” or binge exposure. Individuals suffering from an
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AUD binge drink in a more episodic fashion and show signs of alcohol-induced
neurodegeneration in the absence of systemic influences (Epstein et al. 2004; Hunt
1993; Paradis et al. 2009). This drinking pattern makes understanding the nature of
secondary exposure vital to a full view of the effects of microglia in neurodegeneration. If
ethanol alone potentiates the microglial response, it could be indicative of a feedforward/back process such that repeated exposure causes a loop of activation and elicits
a microglial response that is more proinflammatory and damaging in nature (Crews et al.
2011).
The current experiments examine how repeated ethanol exposure affects
microglia. Specifically, this study uses both functional and morphological indices to
determine the level of microglial activation in the hippocampus and entorhinal cortex,
regions damaged in this binge paradigm (Collins et al. 1996; Kelso et al. 2011; Obernier
2002). The level of activation was assessed to determine if ethanol alone could
potentiate the microglial response and switch the low-grade phenotype elicited by the
Majchrowicz model to a more classical activation state with repeated exposure.

MATERIALS AND METHODS
Alcohol Administration Model
A total of 33 adult male Sprague-Dawley rats (Table 4.1; Charles River
Laboratories, Raleigh, NC) were used in these experiments. Procedures performed were
approved by the University of Kentucky Institutional Animal Care and Use Committee
and were within the Guidelines for the Care and Use of Laboratory Animals (NRC 1996).
Animals were 275-300g upon arrival and were pair-housed in a University of Kentucky
AALAC accredited vivarium with a 12h light:dark cycle. Rats were allowed to acclimate
to the vivarium for two days followed by three days of handling before any
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experimentation. During this acclimation period, animals had ad libitum food and water
access.
Rats were divided into four groups of comparable weights. As shown in Table
4.1, three of the four groups were subjected to a modified version of the Majchrowicz
AUD model. This model has previously been described in chapter two, and the binge
methods used in these experiments were identical. Animals underwent the four-day
Majchrowicz AUD paradigm with intragastric gavage and were then given seven days of
recovery with ad libitum access to food and water. A seven day recovery period was
chosen because it has previously been shown that microglial activation is elevated to
consistent levels for a week after ethanol exposure (Marshall et al. 2013). Furthermore,
seven days allowed animals to regain body mass loss during intubation procedures.
Following the recovery period the Majchrowicz binge model was repeated giving either
ethanol or control diet (see Table 4.1 for details). The entire treatment period was fifteen
days, only eight of which included intragastric gavage exposure. A separate group had
ad libitum access throughout all periods. For all groups, body weights were assessed
daily during the binge procedures. The percent weight difference was calculated
comparing weights at the start and end of the 15-day treatment period.
To determine BECs, tail blood was collected ninety minutes after the seventh
session of ethanol dosing during the first binge exposure (Binge 1) and at euthanization
(Binge 2) within hours of the final dose. Samples were centrifuged for 5 min at 1800g to
separate plasma from red blood cells and immediately stored at -20˚C to avoid sample
degradation. BECs were determined using 5μL of supernatant serum an AM1 Alcohol
Analyser (Analox, London, UK). Each sample was run in triplicates that were calibrated
against a 300mg/dL external standard. The average of these runs was calculated and
expressed in mg/dL.
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Table 4.1 Treatment Summary
Group
Binge1
Recovery
Binge 2
(4 Days)
(7 Days)
(4 Days)
Ad libitum (n=4)
N/A
N/A
Con/Con (n=10)
Control Diet
Control Diet
Ad libitum food and
water access
Con/EtOH (n=11)
Control Diet
Ethanol Diet
EtOH/EtOH (n=8)
Ethanol Diet
Ethanol Diet
Table 4.1. Animals were divided into four groups. The first group, ad libitum, was allowed
access to food and water throughout all treatment periods. All other groups had four
days of intragastric gavage 3 times a day, a seven-day recovery period, and then a
second treatment period of intragastric gavage. Groups are labeled based on their
treatment such that the Con/Con and EtOH/EtOH group received either control (Con) or
ethanol (EtOH) diet, respectively, during both treatment periods, but the Con/EtOH
group of animals first received control diet and then EtOH diet in the second treatment
period.
Figure 4.1 A Timeline of Animal Treatment

Figure 4.1 A timeline of the binge treatment, recovery, and blood collections that
animals underwent.

Rats were euthanized within hours of their final treatment by rapid decapitation.
Brains were extracted and dissected into two hemispheres on ice. The left hemisphere
was fixed by immersion in 4% paraformaldehyde in PB (pH=7.4) and used in
immunohistochemistry experiments. The right hemisphere, however, was further
dissected such that the hippocampus and entorhinal cortex were removed. Extracted
regions were snap frozen on dry ice for use in cytokine analysis using ELISA.
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Immunohistochemistry
The left hemisphere was sectioned and underwent immunohistochemical
processing identical to the treatment of brains described in previous reports as well as in
chapter two (Marshall et al. 2013). However due to changes in how the brain was
processed (i.e. no perfusions), tissue was incubated in primary antibodies at 4˚C as
follows: mouse anti-OX-6 (1:500, Serotec, Raleigh, NC), mouse anti-ED-1 (1:500;
Serotec), rabbit anti-Iba-1 (1:1000, Wako, Richmond, VA), or mouse anti-OX-42 (1:1000;
Serotec). Primaries were chosen for their specificity for microglia phenotypes as
described in chapter 2 (Table 2.1). Methods for the application of secondary antibody
(biotinylated horse anti-mouse, rat adsorbed, or biotinylated goat anti-rabbit, Vector
Laboratories, Burlingame, CA), avidin-biotin-peroxidase complex (ABC Elite Kit, Vector
Laboratories) and chromagen, DAB (Polysciences, Warrington, PA), were identical for all
primary antibodies and followed previously published methods as well as in chapter two
(Marshall et al. 2013; McClain et al. 2011). Following the final wash, all stained sections
were mounted onto glass slides and dried before being coverslipped with Cytoseal®
(Stephens Scientific, Wayne, NJ).

Quantification
Slides were coded to ensure the experimenter was blinded to treatment
conditions during quantification. OX-42 quantification and qualitative assessments of
ED-1, and OX-6 were identical to methods described in chapter two and previously
reported (Marshall et al. 2013). OX-42 results were averaged and expressed as percent
control.
Iba-1+ cells were quantified in the entorhinal cortex by an automated counting
system, Image Pro Plus 6.3 (Media Cybernetics, Rockville, MD) as previously described;
however, images containing the entire entorhinal cortex were collected at 6.4x between
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using SPOT Advanced™ (SPOT Imaging Solutions, Sterling Heights, MI). The number
of cells per section was averaged and expressed as Iba-1+ cells/section.
Iba-1+ cells within the subregions of the hippocampus were estimated by
unbiased stereological methods as described in previous chapters and were identical to
previously published reports (Marshall et al. 2013). For all stereological quantifications,
coefficient of error ranged from 0.011 to 0.039 and averaged 0.023 ± 0.001
Enzyme Linked Immunosorbent Assay
Tissue collected for ELISA studies was manually homogenized in an ice-cold
lysis buffer (1mL of buffer/50mg of tissue; pH=7.4). The buffer and homogenate
preparation was consistent with other reports as detailed in previous chapters (Marshall
et al. 2013; Rabuffetti et al. 2000). Cytokine protein content in the hippocampus and
entorhinal cortex was determined with an ELISA kit according to the manufacturer’s
instructions for TNF- (Invitrogen product #KRC3011C, Camarillo, CA) and IL-10(
Invitrogen product #KRC0101). These two cytokines were used to understand the pro or
anti-inflammatory nature of microglia, respectively. However, BDNF was only measured
in the hippocampus (Billerica, MA; product #CYT306). Testing only one hemisphere
resulted in a limited sample so only these cytokines or growth factors were assessed.
All samples and standards were run in duplicate. Absorbance was measured at 450nm
for ELISA or at 595nm for the BCA assay on a DXT880 Multimode Detector plate reader
(Beckman Coulter, Brea, CA). The cytokine protein concentration was divided by the
total protein concentration obtained in the BCA assay to correct for differences in tissue
volume and reported as pg of cytokine/ mg of protein.
Statistical Analyses
The data were analyzed and graphed using Prism Version 5.04 (GraphPad
Software, Inc. La Jolla, Ca) and reported as the mean ± standard error of the mean.
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Analyses were considered significantly different if p<0.05. Behavioral scores were
analyzed with a Kruskal Wallis test. All other parametric analyses were analyzed using a
one-way ANOVA with post-hoc Tukey’s multiple comparison tests to compare between
groups if an effect of treatment was observed. Where appropriate, each region of the
hippocampus or entorhinal cortex was considered independent and therefore analyzed
separately. To address the potential additive effects of ethanol, correlation analyses
were conducted looking at the relationship of microglial markers of activation and the
animal model data. Correlation analyses also were conducted comparing cytokine
concentration to immunohistochemical measures of microglia since cytokines
measurements and immunohistochemical quantifications were done within the same
animal. Analysis of immunohistochemical results and ELISA data also allowed for a
better interpretation of the source of cytokines. Correlations were only run within the
Con/EtOH or EtOH/EtOH group if post-hoc analyses showed a significant difference to
control groups. Spearman analyses were used for intoxication behavior scores as they
are nonparametric, while Pearson’s analyses were used for all other factors (i.e. percent
weight difference, BEC, etc.).

RESULTS
Animal Treatment Data
Although the Vanilla Ensure Plus® diet is considered nutritionally complete,
percent difference in weight was calculated to assess whether restricted caloric intake
affected microglia activation (Loncarevic-Vasiljkovic et al. 2012; Tu et al. 2012). Oneway ANOVA indicated that treatment differentially affected percent weight change [F(2,24)
=4.235, p=0.0266] (Table 4.2). Tukey’s post-hoc analysis showed that the percent
weight change differed between all the groups that had intragastric gavage (Con/Con,
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Con/EtOH, and EtOH/EtOH) compared with the ad libitum group. Importantly, post-hoc
tests showed no difference between the weight change in the Con/EtOH and
EtOH/EtOH groups. For the analysis of binge subject data, each binge period per group
was considered independently such that data for animals that received ethanol twice
were analyzed as separate entities. For example, BECs from Binge 1 and 2 for the
EtOH/EtOH were analyzed as separate data points. No differences were detected in
either intoxication score (grand mean=1.6 ± 0.1) or in BECs (grand mean=399.8 ± 12.4
mg/dL) for any of the treatment periods or groups (Table 4.3). However, one-way
ANOVA analysis revealed differences in the average dose per day [F(2,24) =4.235,
p=0.0266]. A post-hoc Tukey’s test indicated a significant difference in the dose per day
during Binge 2 comparing the EtOH/EtOH and Con/EtOH rats (Table 4.3).

Table 4.2 Percent Body Weight Change
Percent Weight
Group
Change
Ad libitum (n=4)
+25.2% ± 1.7
Con/Con (n=10)
+1.0% ± 1.4$
Con/EtOH (n=11)
-6.6% ± 2.1*
EtOH/EtOH (n=8)
-8.7% ± 1.7*
Table 4.2 The percent weight change was calculated for each treatment group. *p < 0.05
compared to ad libitum and Con/Con group; $p<0.05 compared to ad libitum group only.
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Table 4.3 Experiment Three Animal Model Data
Intoxication
Dose Per Day
BEC
Group
behavior
(g/kg/day)
(mg/dl)
(0–5 scale)
Con/EtOH
1.8 ± 0.1
9.6 ± 0.2
422.2 ± 21.1
EtOH/EtOH Binge 1
1.7 ± 0.1
9.9 ± 0.4
378.7 ± 17.7
EtOH/EtOH Binge 2
1.3 ± 0.2
11.0 ± 0.5#
390.3 ± 24.02
Table 4.3 Measures of various intoxication parameters of the Majchrowicz model are
statistically similar between all treatment groups excluding the dose per day given to
EtOH/EtOH animals during the second treatment compared with the dose per day given
to the Con/EtOH group. Since all other parameters are similar, it is not likely that the
dose per day affected any other outcome measures. #p < 0.05 compared to Con/EtOH.
OX-42 immunoreactivity increased by EtOH exposure
OX-42 expression was examined to determine whether microglia were further or
differentially activated following secondary binge exposure. OX-42 positive cells were
apparent in all treatment groups, which is consistent with its constitutive expression in all
types of microglia (Akiyama and McGeer 1990). However, there was a visibly distinct
increase in immunoreactivity in ethanol treated animals and an apparent morphological
change indicated by a reduction in the ramification but a thickening of the processes in
the ethanol animals compared with the controls (Figure 4.2, A-F). One-way ANOVAs
indicated a significant effect of treatment in the CA1 [F(3,29) =16.81, p<0.0001], CA2/3
[F(3,29) =18.34, p<0.0001], and DG [F(3,29) =14.43, p<0.0001] fields, as well as in the
entorhinal cortex [F(3,28) =19.01, p<0.0001]. As expected based on the data detailed in
chapter two, Post-hoc Tukey’s tests indicated a significant increase in OX-42 density in
all ethanol treated groups’ in all regions compared with the control or ad libitum group.
Importantly, the EtOH/EtOH group showed greater immunoreactivity than Con/EtOH in
all regions except the DG. Moreover, no difference in staining was observed between ad
libitum animals and the Con/Con group. Correlation analyses of binge model measure
with OX-42 immunoreactivity were run within the EtOH/EtOH and Con/EtOH group
(Table 4.4).
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Figure 4.2 Increased OX-42 immunoreactivity following EtOH Exposure
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Figure 4.2. CD11b is upregulated in the hippocampus and entorhinal cortex as shown in
representative photomicrographs of the (A-C) hippocampal DG and the (D-F) entorhinal
cortex for (B,E) Con/EtOH (C, F) and EtOH/EtOH group compared to (A, D) controls.
Analysis of OX-42 immunoreactivity indicated the EtOH/EtOH group had significantly
more staining than the Con/EtOH group in the: (G) CA1, (H), CA2/3, and (I) DG as well
as the (J) entorhinal cortex. Scale bars=200 μm. *p < 0.05 compared to ad libitum and
Con/Con group; #p< 0.05 compared to Con/EtOH.
Table 4.4 OX-42 Immunoreactivity Correlation Analyses
Correlation
Group Region
Parameter
P-value
Coefficient
EtOH/EtOHIntoxication behavior
S=0.523
0.20
Hippocampus
Dose/Day
P= -0.053
0.90
Total Dose
P= -.0267
0.52
BEC
P=-0.572
0.13
Percent Weight Loss
P=0.249
0.55
Iba-1+ Cells
P= 0.539
0.17
EtOH/EtOHIntoxication behavior
S=0.371
0.36
Entorhinal Cortex
Dose/Day
P= -0.456
0.30
Total Dose
P= -0.575
0.18
BEC
P=0.032
0.94
Percent Weight Loss
P=0.319
0.46
Con/EtOHIntoxication behavior
S=0.433
0.21
Hippocampus
Dose/Day
P= -0.321
0.37
BEC
P=0.424
0.22
Percent Weight Loss
P=-0.222
0.54
Con/EtOH-Entorhinal
Intoxication behavior
S=0.628
0.06
Cortex
Dose/Day
P= -0.488
0.15
BEC
P=-0.082
0.82
Percent Weight Loss
P=0.029
0.94
Table 4.4 No significant correlations were found between OX-42 immunoreactivity and
animal model data or cell number.
Lack of ED-1 or OX-6 positive cells
The ED-1 antibody was used to recognize phagocytic microglia, whereas OX-6
was used to visualize the upregulation of MHC-II (Graeber and Streit 2009; Raivich et al.
1999a). No groups appeared to have an upregulation of ED-1 (Figure 4.3) or OX-6
(Figure 4.4) positive cells within the hippocampus or entorhinal cortex. There was,
however, one EtOH/EtOH treated animal that several OX-6 cells within the more
posterior regions of the hippocampus and entorhinal cortex (Figure 4.4 D, H). The
animal with increased OX-6 cells was not an outlier for any intoxication parameter
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including BEC, intoxication behavior, or ethanol dose per day. Interestingly, the
morphology of these cells still appeared to be characteristic of the low grade, partial
activation state of microglia. ED-1 and OX-6 positive cells were visible in blood vessels,
the hippocampal fissure, and along the meninges in all treatment groups (Figure 4.3;
4.4) similar to that previously reported following binge ethanol exposure (Marshall et al.
2013; Nixon et al. 2008). Thus, repeated exposure of ethanol treatment failed to
significantly induce phagocytic-stage microglia or increase MHC-II in the brain
parenchyma.

Figure 4.3 Lack of ED-1 Positive Cells

Figure 4.3. ED-1 was not visible in the parenchyma of the (A–C) hippocampus or (D–F)
entorhinal cortex as seen in representative photomicrographs in (A, D) controls, (B,E)
Con/EtOH (C, F) or EtOH/EtOH group. ED-1 positive cells could be seen along the blood
vessels as shown in the inset of B. Scale bars=200 μm.
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Figure 4.4 Lack of OX-6 Positive Cells
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Figure 4.4. No OX-6 positive cells were visualized regardless of treatment in the majority
of animals as seen in representative photomicrographs of the (A-C) hippocampus or (EH) entorhinal cortex in (A, E) controls, (B,F) Con/EtOH (C, G) or EtOH/EtOH group.
However, OX-6 positive cells could be seen along blood vessels as shown in the inset of
B. One EtOH/EtOH animal showed upregulation of OX-6 in both the (D) hippocampus
and (H) entorhinal cortex. Scale bars= 200 μm.
Differential effects of treatment on number of microglia
Stereology and automated cell counts were used to determine whether repeated
ethanol exposure affects the number of microglia during exposure (Figure 4.5). Oneway ANOVAs indicated a significant effect of treatment in the CA1 [F(3,29) =161.6,
p<0.0001], CA2/3 [F(3,29) =17.99, p<0.0001], DG [F(3,29) =69.98, p<0.0001] fields, as well
as in entorhinal cortex [F(3,28) =6.78, p=0.0014]. Post-hoc Tukey’s tests indicated a
significant increase in the number of Iba-1+ cells in all subregions of the hippocampus in
the EtOH/EtOH group compared with all other groups. However, in the entorhinal cortex
microglia cells in the EtOH/EtOH group were decreased compared to the ad libitum and
control groups but was similar to the number seen in Con/EtOH treated animals (Figure
4.5). Consistent with data discussed in chapter 3, Tukey’s multiple comparison tests
showed that Con/EtOH rats had decreased Iba-1+ cells in all regions measured
compared to Con/Con and ad libitum groups (Figure 4.5). Because the number of
microglia can affect immunoreactivity, an analysis of the number of microglia compared
with OX-42 immunoreactivity was run, but no significant relationship was determined
(Table 4.4)
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Figure 4.5 Differential effects of Repeated Exposure on the number of Microglia

Figure 4.5. Stereological estimates indicate an increase in the number of microglia in the
EtOH/EtOH group in the (A) CA1 (B) CA2/CA3, and (C) DG compared with all other
treatment groups. However, the number of microglia in the Con/EtOH group was
consistently decreased throughout the hippocampus. In the (D) entorhinal cortex,
microglia cells were decreased in both the Con/EtOH and EtOH/EtOH treated groups
compared to both the ad libitum and Con/Con groups. *p < 0.05 compared to ad libitum
and Con/Con group; # p < 0.05 compared to Con/EtOH.
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Increased TNF-α in EtOH/EtOH group
ELISAs were used to assess the functional state of microglia, specifically the
anti-inflammatory cytokine, IL-10, and the proinflammatory cytokine TNF-α. Consistent
with results in chapter two, no changes were seen in IL-10 during intoxication in either
the hippocampus or the entorhinal cortex in the Con/EtOH or EtOH/EtOH groups (Figure
4.5). However, a one-way ANOVA on TNF-α concentrations indicated a significant effect
of treatment in the hippocampus [F(3,28) =4.658, p=0.0092] but not the entorhinal cortex.
Post-hoc Tukey’s tests indicated a significant increase in TNF-α in the hippocampus in
the EtOH/EtOH group compared with all other groups (Figure 4.6). The distribution of
TNF-α concentrations observed in the EtOH/EtOH group did not fit a normal distribution
and appeared to be bimodal. Correlation analyses of binge parameters as well as
immunohistochemical results were run within the EtOH/EtOH group to further probe the
bimodal distribution of the TNF-α concentrations within the hippocampus (Table 4.5).
BECs correlated with TNF-α concentration [P(8) =0.807, p=.0155] (Table 4.5; Figure 4.7).
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Figure 4.6 Increased TNF-α in EtOH/EtOH group

Figure 4.6. Concentrations of (A, B) IL-10 and (C, D) TNF-α were determined by ELISA
in both the hippocampus (A, C) and entorhinal cortex (B, D). No change in IL-10 was
measured in either the hippocampus or entorhinal cortex, but at least a 2.7 fold increase
in TNF- α was measured in the (C) hippocampus in the EtOH/EtOH group compared
with all other groups. No change in TNF-α was seen in (D) entorhinal cortex. *p < 0.05
compared to all groups.
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Table 4.5 Select Hippocampal Cytokine and Growth Factor Correlation Analyses
Cytokine
Correlation
Parameter
P-value
Coefficient
TNF-α - EtOH/EtOH
Intoxication behavior
S=0.371
0.36
Dose/Day
P= -0.544
0.16
Total Dose
P= -.3545
0.39
0.02*
BEC
P=0.807
Percent Weight Loss
P=0.610
0.11
OX-42
P= -0.139
0.74
immunoreactivity
Iba-1+ Cells
P= -0.372
0.36
BDNF-Con/EtOH
Intoxication behavior
S= -0.421
0.23
Dose/Day
P=0.166
0.65
BEC
P=0.166
0.64
Percent Weight Loss
P=0.395
0.26
OX-42
P=0.253
0.48
immunoreactivity
0.003*
Iba-1+ Cells
P=0.835
BDNF-EtOH/EtOH
Intoxication behavior
S=0.216
0.62
Dose/Day
P= -0.149
0.73
Total Dose
P= -0.144
0.73
BEC
P= 0.298
0.47
Percent Weight Loss
P= -0.473
0.24
OX-42
P= -0.254
0.54
immunoreactivity
Iba-1+ Cells
P=0.224
0.59
Table 4.5 Correlations were used to examine the relationship between cytokines versus
immunohistochemical markers of microglial response and animal model data. TNF-α and
BECs in the EtOH/EtOH group as well as the number of microglia and BDNF in the
Con/EtOH group, both were correlated significantly.
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Figure 4.7 TNF-α and BEC Correlation of EtOH/EtOH group
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Figure 4.7 A positive correlation was observed between BEC and TNF-α concentration.
Animals with BECs over 400mg/dL appear to have an increase in TNF-α.

Differential effects of treatment on BDNF concentrations
BDNF concentrations were assessed as a quick measure of the health of the
neuronal environment in the hippocampus as BDNF is associated with neuronal cell
survival (Lipsky and Marini 2007; Loeliger et al. 2008). A one-way ANOVA of BDNF
concentrations indicated a significant effect of treatment in the hippocampus [F(3,28)
=19.00, p<0.0001]. Post-hoc Tukey’s tests indicated a 20% increase in BDNF
concentration in the hippocampus in the EtOH/EtOH compared with all other groups
(Figure 4.8). Consistent with data presented in chapter three (Figure 3.4), Tukey’s test
indicated Con/EtOH rats had decreased concentrations of BDNF compared to both the
Con/Con and ad libitum group (Figure 4.8). Correlations between binge animal model
data as well as markers of microglial activation were run versus BDNF concentrations for
both the Con/EtOH and EtOH/EtOH group (Table 4.4). The estimated total number of
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microglia [P(10) =0.835, p=.003] was correlated to BDNF concentrations only in the
Con/EtOH group (Table 4.5; Figure 4.9).
Figure 4.8 Differential effects of Ethanol Exposure duration on BDNF

Figure 4.8 Concentrations of BDNF were determined by ELISA in the hippocampus.
BDNF was decreased by approximately 15% in Con/EtOH treated animals compared
with Con/Con or ad libitum groups but increased by 20% of in the EtOH/EtOH groups.
*p < 0.05 in relation to ad libitum and Con/Con group; # p < 0.05 in relation to Con/EtOH.
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Figure 4.9 BDNF and Stereological Estimates Correlation of Con/EtOH group
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Figure 4.9 A positive correlation was observed between hippocampal estimates of
microglia number and BDNF concentrations in the Con/EtOH. A decline in the number of
microglia cells was related to decreases in BDNF concentrations.

DISCUSSION
During abstinence, the Majchrowicz model of alcohol-induced neurodegeneration
results in microglia that are partially activated. Partially activated microglia can be
involved in recovery mechanisms, but an alternative interpretation of partial microglial
activation is that the microglia are primed. The studies herein further develop our
understanding of what may occur within the alcoholic population by examining the
effects of repeated binge exposure in a rodent model. Two criticisms of Majchrowicz
model is that animals have prolonged periods of intoxication and that it’s just one
exposure period whereas human alcoholics drink in a more episodic nature such that
there are periods of high BECs with but also periods of abstinence (Harford et al. 2005;
Hunt 1993; White et al. 2006). Therefore, these experiments tested whether the partially
activated microglia previously observed following four days of ethanol exposure were
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primed and could be potentiated by a second insult of ethanol exposure. Increased OX42 immunoreactivity as well as differential TNF-α production in the EtOH/EtOH group
compared to the Con/EtOH group supports the major finding of these studies that a
subsequent binge exposure can potentiate alcohol-induced microglial activation. Given
that people often drink in an episodic binge pattern, potentiation in this model, with just
two exposure experiences, suggests that chronic alcohol exposure may lead to even
more dynamic microglial activation over time.
The first evidence of this differential response observed here was increased
immunoreactivity of the OX-42 antibody. Ethanol exposure has been shown previously
to cause increased OX-42 staining (Fernandez-Lizarbe et al. 2009; Marshall et al. 2013;
Zhao et al. 2013). This study confirms those findings but furthers that work by showing
that a second hit of binge ethanol exposure further increases OX-42 immunoreactivity.
Increased OX-42 immunoreactivity is indicative of an upregulation of the CR3 receptor
which can lead to increased phagocytic activity (Hynes 1992; Morioka et al. 1992;
Robinson et al. 1986). Because the switch from low-grade activation to classical
activation is CR3 dependent (Ramaglia et al. 2012), the differentially increased
upregulation of CR3 caused by secondary ethanol exposure in the EtOH/EtOH group
indicated that more classical signs of activation would also be present. However, despite
the potentiation of the CR3 receptor density, no changes in ED-1 or OX-6 staining were
seen following the second binge. The lack of ED-1 upregulation concurs with many other
studies that do not show signs of phagocytosis following ethanol exposure (Marshall et
al. 2013; McClain et al. 2011; Nixon et al. 2008). However, one recent but controversial
report, due to the lack of animal recovery and mortality, has shown that more chronic
ethanol exposure results in phagocytic, classical activation of microglia (Zhao et al.
2013). Furthermore, the OX-6 positive cells seen in one EtOH/EtOH animal, while an
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anomaly in this study, may be a sign of a progression of activation from a low-grade to a
more classical activation state as seen in other models with more prolonged intermittent
exposure (Ward et al. 2009a).
Microglial activation not only causes changes in receptor density but also affects
secreted cytokines (Carson et al. 2007), therefore hallmark pro- and anti-inflammatory
cytokines were measured to understand the type of microglial activation associated with
a second binge ethanol exposure. No change in IL-10 concentration was caused by
ethanol exposure in either group within the hippocampus or entorhinal cortex. The lack
of IL-10 response concurs with data presented in chapter two that during intoxication
anti-inflammatory cytokines are not changed (Figure 2.6; Marshall et al. 2013). That
same report showed an increase in IL-10 following seven days of abstinence (Marshall
et al. 2013). Whether the normalized levels of IL-10 reported here are caused by
secondary ethanol exposure or a byproduct of a transient increase in anti-inflammatory
cytokines cannot be answered by the current experiments. However, the normalized
levels of IL-10 does indicate that primed microglia progress are not secreting antiinflammatory cytokines. Instead an increase in TNF-α, secreted by proinflammatory
microglia, was seen in the EtOH/EtOH group compared with all other groups in the
hippocampus. Although the methods used cannot directly tie changes in TNF-α
concentration to microglia, the change in the cytokine profile, at minimum, suggests a
proinflammatory state within the hippocampus caused by secondary ethanol exposure.
An increased proinflammatory state may be reflective of the primed state of microglia
observed following secondary ethanol exposure.
The differences in dose per day among the ethanol treated animals did not
appear to have an effect as correlative studies looking at dose per day did not have an
effect on microglia markers in either the Con/EtOH or EtOH/EtOH group. Moreover, the
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total dose given to the EtOH/EtOH animals did not correlate to increases in any markers
of microglial activation. This lack of correlation suggests the potentiation in OX-42
immunoreactivity in the EtOH/EtOH group were not due to a simple additive effect of
alcohol. Correlation studies were also used to examine the upregulation of TNF-α
observed in some but not all animals. Although upregulation of the CR3 receptor is
associated with increased activation and the observed increase in microglia number
could affect basal cytokine levels, the increase in TNF-α levels were not associated with
either parameter. BECs, however, did have a significant relationship to TNF-α levels.
The mechanism by which BECs could influence TNF-α expression was not determined
in these studies, but higher BECs can alter the way ethanol is metabolized. At higher
BEC, ethanol is metabolized within the brain more readily by CYP2E1 which is an
alternative mechanism of increased ROS production in alcoholics (Haorah et al. 2008;
Ronis et al. 1993; Zhong et al. 2012). An increase in ROS production caused by ethanol
metabolism could also explain differences seen between these data and others that
show more robust classical activation of microglia (Qin and Crews 2012b).
Data presented in chapter three showed that intoxication caused a decrease in
microglia number. Similar to data described in chapter three, the Con/EtOH group had
decreased numbers of microglia. This reduction may be due to degeneration or loss of
microglia and dysfunction in both the hippocampus and entorhinal cortex. However,
these experiments were conducted to determine whether primed microglia were still
susceptible to the decreases associated with intoxication with a second binge event.
The EtOH/EtOH group actually showed an elevated number of microglia within the
hippocampus compared with the control groups and Con/EtOH animals. These data
agree with increased microglia numbers seen in human alcoholics (He and Crews 2008).
However, interpreting these data is complicated by the fact microglia begin to proliferate
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in the hippocampus 48 hours after the last dose of ethanol (McClain et al. 2011; Nixon et
al. 2008). This proliferation results in increased microglia at the time that the second
binge paradigm began (Marshall et al. 2013), but the lack of decrease does allude to the
idea that primed microglia may not be as susceptible to microglial dysfunction or
degeneration. Unlike in the hippocampus, microglia proliferation in the entorhinal cortex
does not cause an increase in cell number at the time in which the second exposure
starts (Marshall et al. 2013). The similar number of microglia observed among the
Con/EtOH and EtOH/EtOH group in the entorhinal cortex indicates that despite having a
more robust response (increased OX-42) that microglia are still susceptible to the
damaging effects of alcohol during intoxication. The differential susceptibility of brain
regions may be due to differences in the type of activation between the two regions as
the hippocampus was shown to have more classical signs of activation (TNF-α).
Increases in microglia, such as the sustained increase in hippocampal microglia
observed in the EtOH/EtOH group, have been described as causative in increased
neuroinflammatory activity in other neurodegenerative disorders (Frank-Cannon et al.
2009). Importantly, increased microglia in the hippocampus support the theory that
repeated ethanol exposure causes a differential response in microglia primed by
previous exposure.
A more chronic model of alcohol exposure using intragastric exposure also
suggests that microglia classical signs of activation, but there is controversy regarding
interpretations of the data due to the health of animals and their lack of recovery from
the binge model (Zhao et al. 2013). The intragastric gavage method used in this model
can be stressful to animals and results in weight loss due to caloric restriction (Balcombe
et al. 2004; Sharrett-Field et al. 2013a). Both stress and reduced caloric intake can alter
microglial activation (Loncarevic-Vasiljkovic et al. 2012; Sugama 2009; Sugama et al.
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2009). To confirm that changes in microglial activation and cell number were due to
ethanol and not other factors associated with the repeated gavage, a group with ad
libitum access to food and water was assessed and compared with the Con/Con group.
The measures of activation used to assess the microglia were not different in any aspect
between the ad libitum group and the Con/Con group despite the weight loss caused by
intragastric gavage. Furthermore, weight loss did not correlate with any measure of
microglial activation and is therefore probably not a factor in the changes between
Con/EtOH or EtOH/EtOH animals.
Upregulation of indices of microglial activation and number coincide with changes
in the concentration of the growth factor, BDNF. The pattern seen in hippocampal BDNF
alterations mimics the changes seen in microglia cell number and activation. In the
Con/EtOH group, BDNF was decreased as cell number decreased; however when
microglia are more activated and numbers are increased, EtOH/EtOH treated animals
had an increase in BDNF concentration. Increases in BDNF may promote cell survival
(Lipsky and Marini 2007; Loeliger et al. 2008). Because BDNF is secreted by astrocytes,
neurons, and other cells within the CNS (Bejot et al. 2011; Lau and Yu 2001), the
methods used cannot definitively state that changes in BDNF concentrations are due to
microglia. However, in the Con/EtOH the number of microglia was positively correlated
to BDNF concentration. The correlation between microglia loss and BDNF reduction
supports the idea that microglial dysfunction and subsequent loss of trophic factors is a
concern in alcoholic brain damage. The lack of correlation in the EtOH/EtOH group may
be due to increased TNF-α concentration on the release of BDNF from astrocytes, as
astrocytes are also more reactive in abstinence from alcohol exposure (Kelso et al.
2011; Saha et al. 2006). Regardless of the source, this increased BDNF indicates that

117

both in proinflammatory cytokines and proneurogenic growth factors are present within
the milieu of the hippocampus after a second binge ethanol treatment.
Whether the alcohol-induced microglial activation shown within affords
neuroprotection or leads to increased damage cannot be determined from these studies.
At a glance, it would appear that increased microglial activation especially with increased
secretions of TNF-α would be detrimental to the neuronal environment as shown in
other neurodegenerative diseases (Block and Hong 2005). However, an acute initial
microglial response is necessary for recovery and the removal of neuronal debris
(Badoer 2010; Nimmerjahn et al. 2005; Streit 2005). The loss of microglia during
intoxication was discussed in chapter 3 and was purported to be associated with a loss
of homeostatic properties of microglia; however, in the hippocampus microglia number
remain elevated in response to damage. This elevation in cell number may suggest that
microglia are actually responding more appropriately to the alcohol-induced brain
damage. Moreover, studies with more chronic binge alcohol exposure produced
phagocytic microglia and proinflammatory cytokines that were transient and present
mainly during intoxication (Zhao et al. 2013). The transient nature of this response
indicates that microglia are actually responding appropriately to neuronal damage. If the
upregulation of TNF-α seen in the EtOH//EtOH group is only transient it would indicate
that response of microglia is only induced by neuronal injury and that activation occurs
as a rehabilitative event to restore homeostasis. For example, as described earlier,
acute TNF-α upregulation can induce BDNF production in astrocytes and therein afford
neuroprotection (Saha et al. 2006).
The potentiated microglia activation seen in this double binge AUD model
suggests that the microglial response can be altered by ethanol alone. Whether this
increased response causes microglia to respond more appropriately to noxious stimuli or
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if it makes the brain more susceptible to ongoing neuroinflammation cannot be
determined by these experiments. However, because microglia have the capacity to
maintain low grade activation for extensive periods following alcohol exposure (Marshall
et al. 2013; Obernier et al. 2002b), the episodic nature of binge drinking may lead to a
cycle of repeated priming activity within individuals suffering from an AUD. Furthermore,
instances of systemic inflammation and ROS production may act to perturb already
primed microglia (Cunningham 2013; Cunningham et al. 2005). These data do not
conclusively indicate microglial activation as a source of alcohol-induced
neurodegeneration, but this study does show that repeated ethanol exposure potentiates
microglial activity. The primed, persistent nature of microglia following alcohol-induced
neurodegeneration observed in this model may still be a source of neurodegeneration in
human alcoholics especially when other neuroimmunomodulatory factors are present
and the AUD is more chronic in nature.

Copyright © S. Alex Marshall
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OVERALL CONCLUSIONS
Review
Alcoholism is a chronic disease, which permeates various aspects of society.
Chronic ethanol exposure leads to neuroplastic changes that drive the development of
an AUD. Elucidating these neurobiological changes has led to the development of
therapies that ameliorate craving and/or the rewarding effects of alcohol, but currently no
therapies specifically treat the neurodegeneration caused by excessive alcohol
consumption. Alcohol-induced neurodegeneration is associated with cognitive deficits
that compromise the executive function and the working memory. These cognitive
deficits caused by neuronal loss can perpetuate the seeking of alcohol and therefore
have been hypothesized as contributing to the development of an AUD (Crews 2012;
Crews et al. 2011). Like other neuroadaptations within AUDs, elucidating the
mechanisms that lead to alcohol-induced neurodegeneration may be a novel therapeutic
target for the treatment of alcoholism.
Neuroinflammation is a key factor in many neurodegenerative diseases like
Alzheimer’s and Parkinson’s Diseases and recently has been proposed as a mechanism
of alcohol-induced neurodegeneration. The current understanding of alcohol’s effects on
the neuroimmune system in alcoholics does not definitively indicate that
neuroinflammation occurs within AUDs; however, they do suggest that alcohol alters the
neuroimmune system. One such effect is the activation of microglia. Microglial activation
has long been considered a hallmark of neuroinflammation, but understanding the
dynamic nature of microglia within the context of a disease is crucial to understanding
how they may be involved with neurodegeneration and/or homeostatic recovery
mechanisms. Therefore, these studies examined microglial activation within an AUD
model of alcohol-induced neurodegeneration looking at both the initiation and level of
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activation as well as the ability of persisting microglia activation to exacerbate the
neuroinflammatory events.

Aim 1: Determine the phenotype of microglia reactivity following binge ethanol exposure
in the Majchrowicz model of an AUD (Chapter 2).
The hypothesis that binge ethanol exposure induces low-grade microglia
activation was supported by experiments herein. Increased expression of CR3 (OX-42)
and TSPO as well as anti-inflammatory cytokines without an increased immunoreactivity
of ED-1 or OX-6 suggest that acute binge ethanol exposure does not elicit classically
activated microglia but shows signs of partial activation. Specifically, our data indicates
that microglia are elicited to stage2b of the Raivich scale. The lack of classically
activated microglia in conjunction with no BBB disruption therefore does not meet the
criteria for neuroinflammation.

Aim 2. Determine the earliest indices of microglial activation in the Majchrowicz model of
an AUD (Chapter 3).
The hypothesis that the initial microglial response occurs subsequent to
indications of neurodegeneration was supported by increased binding of [3H]-PK-11195
after two but not one days of exposure. Albeit not a part of the original hypothesis goals,
an unexpected discovery of decreased microglia number and evidence of dystrophy
suggests a type of microglial dysfunction in a second population despite activation in
some microglia.

Aim 3. Determine if alcohol-induced microglia reactivity following the Majchrowicz model
is “primed” (Chapter 4).
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The hypothesis that a second binge exposure would potentiate the microglia
response seen in recovery from the Majchrowicz model was supported, but not robustly.
However, functional and immunohistochemical assessments of activation differed on
whether the potentiation induced classical signs of activation. OX-42 immunoreactivity
was more robust following two binge ethanol exposures paradigms than with a single
binge paradigm, but neither ED-1 nor OX-6 was increased by secondary binge ethanol
exposure. However, ELISA studies showed that TNF-α was increased only after the
second binge treatment. This change in response suggests that the initial response of
microglia in the Majchrowicz model is primed.
Discussion
The purpose of this dissertation was to investigate the effects of ethanol on
microglia within the context of an AUD model known to cause neurodegeneration. To
synthesize the findings within this dissertation within a larger scheme, the effects of
ethanol on microglia will be considered within either the context of intoxication or
abstinence. Microglial responses were studied with an emphasis on the phenotype of
microglial activation and the initiation and duration of activation. Together these
characteristics of microglial activation can be used to infer the contributions of microglia
in alcohol-induced brain damage. The data reported here suggest at least three states of
microglia that may contribute to either brain damage or recovery from damage:
dysfunctional, neurotrophic, and primed.
Microglial Dysfunction
In chapters two and three, the data showing increases in CR3 and/or TSPO
without signs of classical activation agree that microglia are activated to a low-grade
state in response to alcohol-induced neuronal damage. This alternative activation state
of microglia is not indicative of the classical pathways of microglia leading to
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neurodegeneration (Carson et al. 2007). However, the reductions in the number of
microglia and the appearance of dystrophic microglia reported in chapter three indicate
that despite microglial activation that a subset of microglial cells is dying. As previously
discussed, these findings suggest that binge ethanol exposure could disrupt the normal
function of the neuroimmune system. Following damage, microglia provide immediate
neuronal support by promoting anti-inflammatory mechanisms, secreting neurotrophic
factors, and/or through proinflammatory activation removing cellular debris (Streit
2002a). The reduction in the number and/or function microglia could affect these
recovery mechanisms afforded by microglia and be a source of damage. This
hypothesis is an alternative source of neurodegeneration to the typically described
neuroinflammatory pathways that are thought to be associated with alcohol abuse
(Crews 2012; Crews et al. 2011; Streit et al. 2009). While this dissertation does not
specifically look into the mechanisms by which dysfunction of microglia may cause
neurodegeneration, the role of microglia in neurogenesis and glutamate reuptake are at
least two ways in which a dysfunctional neuroimmune response could lead to alcoholinduced neurodegeneration.
It has been shown that a deficiency in microglia disrupts neurogenic processes
and reduces recovery from neuronal damage (Wainwright et al. 2009). Activated
microglia migrate following neuronal damage and secrete cytokines and growth factors
associated with supporting the neurogenic niche in the hippocampus (Neumann et al.
2006). However in this AUD model, the hippocampal microglia “nursing” response to
increase neurotrophic factors such as IL-10 and TGF-β was not observed immediately in
conjunction with signs of neurodegeneration (Hayes et al. 2013; Streit 2002a; Takayama
and Ueda 2005). The reduction in microglia and the lack of neurotrophic support seen
herein during acute intoxication may be involved with the interruption of neurogenic seen
123

during intoxication (Morris et al. 2010a; Nixon and Crews 2002). In particular, decreased
levels of BDNF seen during intoxication would decrease newly born cell survival and
provides indirect evidence of the potential role of microglia in the reduction of adult
neurogenesis observed in this AUD model (Lipsky and Marini 2007; Loeliger et al. 2008;
Mitchell 1999).
The relationship between microglia and glutamate concentration was not
examined in this study but represents another way in which a reduction in microglia
number could potentially affect neuroadaptations seen following alcohol exposure.
Activated microglia upregulate GLT-1 leading to the amelioration of excessive glutamate
levels (Persson et al. 2005; van Landeghem et al. 2001). However, the reduction in
microglia number in damaged regions may be a source of disrupted uptake of glutamate.
Since alcohol withdrawal is associated with excess glutamate concentrations, the
transient decrease in microglia number observed during intoxication in chapter three
may be a factor in glutamate excitotoxicity. Specifically, the idea that alcohol prevents
microglial reuptake of glutamates provides further alludes that the loss of microglial may
be a source of neurodegeneration (Gras et al. 2003). Activated astrocytes have been
shown to increase their glutamate uptake in response to ethanol exposure (MiguelHidalgo 2006; Mulholland et al. 2009; Smith 1997), but the potential role of microglia in
recovery from glutamate excitotoxicity caused by ethanol exposure remains elusive.
Neurotrophic Microglial
Fortunately, neuronal deficits caused by binge alcohol exposure are partially
recovered during abstinence (Zahr et al. 2010b). This recovery in the hippocampus is
thought to be afforded in part to reactive neurogenesis (Crews and Nixon 2009; Nixon
and Crews 2004; Zahr et al. 2010b). Intriguingly, the level of microglia activation
observed during abstinence in chapter two suggests that microglia may participate in
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recovery during abstinence by promoting neurogenesis (Kohman and Rhodes 2013;
Varnum and Ikezu 2012). The increase in the proneurogenic cytokines IL-10 and TGF-β
reported in chapter two occurs concurrently with evidence of neuroprogenitor cell
proliferation (McClain et al. 2013; Nixon and Crews 2004). However, coincident timing
alone is not enough to distinctly determine whether these cytokines are involved with
neuronal proliferation or the survival of neurons, but evidence from other fields with
reactive neurogenesis suggest that such anti-inflammatory cytokines promote the
survival and or proliferation of newly populated cells (Battista et al. 2006; Ekdahl et al.
2009; Kiyota et al. 2012). A direct relationship between partially activated microglia and
reactive neurogenesis in this AUD model is a point of interest and should be considered
in the future studies.
Primed Microglia
Partially activated microglia can also be primed and exacerbate the
neuroimmune response upon subsequent insults (Bilbo and Schwarz 2009; Norden and
Godbout 2013). The potential of partially activated microglia to exacerbate the
neuroimmune reaction is particularly of concern given the enduring nature of microglial
activation. As described in chapter two, CR3 (OX-42) was upregulated for at least
twenty-eight days ethanol exposure (Marshall et al. 2013). Independent studies agree
that ethanol-induced microglial activation persists into protracted abstinence (Obernier et
al. 2002b). This prolonged activation of microglia led to the studies performed in chapter
four determining whether the microglia response was primed and would react differently
to other immunological stimuli. Using ethanol as both the initial and secondary
neuroimmunomodulator, data collected suggested that alcohol exposure does result in a
primed state of microglia such that chronic alcohol exposure may result in more robust
responses over time. These studies do not indicate whether this potentiated
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neuroimmune response endures into abstinence and would truly create an environment
of chronic neuroinflammatory state. Chronic microglial activation would perpetuate
neurodegenerative cell signaling cascades. However, examinations of microglia
following repeated bouts of binge treatment imply that the proinflammatory state is only
transient (Zhao et al. 2013). The transient proinflammatory response observed following
repeated binge paradigms may actually be involved in homeostasis by removal of
cellular debris as phagocytic microglia were seen in other models or by inducing
neurotrophic factor release from other cell types.
Although these studies show specifically that ethanol alone can exacerbate a
primed microglial response, others have shown that alcohol-induced microglial activation
can be exacerbated by systemic inflammation (Qin et al. 2008). It is important in
considering the implications of the alcohol-induced primed microglia state seen herein
that the systemic immune system can exert effects on the CNS neuroimmune response
making it more susceptible to damage (Drake et al. 2011; Murray et al. 2013). This
influence would be particularly critical in complicated alcoholics who may have liver
damage or a comprised BBB (Crews et al. 2011; Qin et al. 2008; Qin et al. 2013). If
immune challenge in the peripheral organ systems initiated an immune response,
alcohol-induced primed microglia may surmount a response in the absence of neuronal
damage. This response to noxious stimuli from the periphery may then cause damage to
healthy tissue.
Alcohol-Induced Microglial Neuroadaptation
The differential response of microglia with respect to duration of exposure as well
as in abstinence or intoxication is comparable to other neuroadaptations having
differential outcomes with acute versus chronic exposure and with intoxication versus
withdrawal/abstinence (Vengeliene et al. 2008). For example, whereas acute ethanol
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inhibits the glutamate receptor, chronic ethanol causes neuroplastic changes that result
in an increase in glutamatergic signaling over time (Vengeliene et al. 2008). Likewise,
the data presented imply that acute alcohol intoxication initially inhibits or at least
disrupts normal neuroimmune function, but chronic ethanol exposure results in a more
proinflammatory response. Figure 5.1 summarizes the response of microglia seen
within. The differential response between acute and chronic ethanol exposure aligns with
the idea that ethanol causes neuroplastic changes in the neuroimmune system. Because
ameliorating alcohol-induced neuroadaptations has proven to be effective in treating
AUDs, so may controlling the neuroimmune response of alcoholics may afford
neuroprotection. The neuroimmune system and particularly microglial activation remains
a target of interest in reducing the neurodegeneration associated with AUDs.
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Figure 5.1 Microglial Morphology & Function in an AUD Model
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Figure 5.1 A depiction of the microglial response seen within these studies. Binge
treatment inhibited microglial function, but during abstinence microglia become partially
activated and secrete neurotrophic factor. The persisting, primed nature of this activation
however exacerbates microglia activation by a second exposure. Blue represents
dystrophic microglia, thickened cells represent a morphological or protein expression
change, thickened green cells represent the emergence of anti-inflammatory cytokines,
and thickened red cells represent the secretion of proinflammatory cytokines.
Limitations & Future Studies
One of the limitations of these studies was the inability to directly tie the changes
in microglia response to recovery. In chapter two, the data set suggests that microglia
would be involved in recovery during abstinence by promoting neurogenesis. In order to
directly look at this relationship would require knocking down or inhibiting the microglial
response. However, pharmacological treatments for inhibiting partially activated
microglia are limited as therapies are generally directed at inhibiting classical, full
activation of microglia or at promoting the alternative activation. For example, standard
neuroimmunomodulators such as non-steroidal anti-inflammatory drugs and minocycline
both target proinflammatory microglia and can promote the alternative activation state
(Kobayashi et al. 2013; Lee et al. 2010; Wang et al. 2012a). Moreover, these agents
have not been shown to reduce partial activation. However, one way to determine to
whether partially activated microglia observed in abstinence from alcohol exposure are
involved with reactive neurogenesis in vivo is to use an alternative model with transgenic
CCR3 deficient mice such as used in the facial axotomy model (Wainwright et al. 2009).
The facial axotomy model has shown that axonal regeneration is dependent upon the
function of microglia using these mice. As such CCR3 deficient mice may be a useful
tool in understanding the contributions of microglia to reactive neurogenesis, but this
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model would require elucidating a new timeline of neuronal and glial events that has
already been done in the rat model.
A different mechanism by which microglia may afford neuroprotection is the
upregulation of GLT1 and the removal of glutamate (Persson et al. 2005; van
Landeghem et al. 2001). This theory deserves exploration but may not be feasible in the
current model as glutamate excitotoxicity has not been observed in the Majchrowicz
model (Rudolph et al. 1997).
Another limitation of these studies is that naive animals are given a bolus of
ethanol in adulthood. This type of ethanol exposure does not necessarily reflect the
human condition as people generally experiment with lower concentrations of ethanol
during adolescence before consuming the neurotoxic levels used within these
experiments (Guilamo-Ramos et al. 2004; Nixon and McClain 2010). While the perfect
model of alcoholism would include preconditioning with lower concentrations prior to the
bolus, the model of alcohol-induced degeneration use in these studies do at least reflect
the response of microglia to alcohol-induced neuronal damage. Furthermore, even
moderate concentrations of alcohol result in modulations to the neuroimmune system
with in vivo with chronic exposure (Ehrlich et al. 2012) and even acutely in culture
(Collins et al. 2010; Fernandez-Lizarbe et al. 2008). The ability of ethanol to affect this
system at lower concentrations suggests that in the development of an AUD
experimentation with ethanol would also result in a microglial response that may
progress and play a role in the neuroadaptations within the neuroimmune response.
All of these studies were done in males despite the fact that AUD-associated
neurodegeneration is also seen in females. While alcohol-induced degeneration may be
more prevalent in males, females actually are thought to be more susceptible to damage
(Hommer 2003; Prendergast 2004; Sharrett-Field et al. 2013b). The model used in these
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studies does not show differential damage between male and female rats, but others
have shown increased susceptibility in the neuroimmune response to alcohol in models
of AUDs (Alfonso-Loeches et al. 2013). Understanding the role of microglial activation in
female rats would further our understanding of the neuroimmune response and its
relationship to neurodegeneration and recovery in the human population.
Final Comments
The current dissertation work delineates the response of microglia to ethanol
exposure in the most comprehensive manner to date looking at the level of activation
over a timecourse in an AUD model. The results indicate that the microglial response
changes with respect to the duration of exposure as well as whether the observation is
during intoxication or abstinence. While initial intoxication may suppress or disrupt the
neuroimmune response, during abstinence the microglia response recovers. The
phenotype of activations suggests that the microglia would be neurotrophic to the
environment. However, a second binge exacerbates the microglial response due to the
persisting primed microglia from the initial alcohol insult. These data support the idea
that the function of microglia are affected by alcohol and that repeated exposure may
cause a neuroplastic change in the microglial response. Pharmacological interventions
that promote the neurotrophic mechanisms of microglia while simultaneously limiting
their detrimental effects may prove efficacious in recovery from alcohol-induced
neurodegeneration.

Copyright © S. Alex Marshall
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